Ward, P.
10/664367

(FILE 'REGISTRY' ENTERED AT 12:11:48 ON 30 MAR 2005)
L1 STR



Str.

VAR G1=H/X/OH/N/AK/21
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE
L3 681 SEA FILE=REGISTRY SSS FUL L1
L7 STR



VAR G1=H/X/OH/N/AK/21
NODE ATTRIBUTES:
CONNECT IS X2 RC AT 8
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE
L8 50 SEA FILE=REGISTRY SUB=L3 SSS FUL L7

100.0% PROCESSED 681 ITERATIONS 50 ANSWERS
SEARCH TIME: 00.00.01

FILE 'CAPLUS' ENTERED AT 12:13:13 ON 30 MAR 2005
L9 24 S L8

L9 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:29204 CAPLUS
DOCUMENT NUMBER: 142:127562
TITLE: Trp-p8 active compounds and therapeutic treatment methods
INVENTOR(S): Reynolds, Mark; Polakis, Paul
PATENT ASSIGNEE(S): Genentech, Inc., USA
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005002582	A2	20050113	WO 2004-US21509	20040702

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:		
US 2003-484526P	P	20030702
US 2003-491616P	P	20030731

AB Compds. of the disclosure provide compns., which are effective for prophylaxis and treatment of diseases or disorders, such as cell-proliferation, angiogenesis, or apoptosis mediated diseases. The disclosure encompasses compds., analogs, prodrugs, metabolites, and pharmaceutically acceptable salts thereof, pharmaceutical compns., and methods for prophylaxis and treatment of diseases and other maladies or conditions involving cancer, tumors, and like conditions. The disclosure also provides therapeutic methods including the administration of an effective amount of a compound of the disclosure. For example, menthane carboxamides were found to be able to influence the Trp-p8 level and thus had antitumor effect, alone or in combination with other anticancer treatment, especially antibodies.

Searcher : Shears 571-272-2528

IT **36945-98-9**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitumor therapy containing compds. effectively influencing Trp-p8 receptor activity in combination with antibodies)
RN 36945-98-9 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)-(9CI) (CA INDEX NAME)



L9 ANSWER 2 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:818811 CAPLUS
DOCUMENT NUMBER: 142:3872
TITLE: The super-cooling agent icilin reveals a mechanism of coincidence detection by a temperature-sensitive TRP channel
AUTHOR(S): Chuang, Huai-hu; Neuhausser, Werner M.; Julius, David
CORPORATE SOURCE: Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA, 94143, USA
SOURCE: Neuron (2004), 43(6), 859-869
CODEN: NERNET; ISSN: 0896-6273
PUBLISHER: Cell Press
DOCUMENT TYPE: Journal
LANGUAGE: English
AB TRPM8, a member of the transient receptor potential family of ion channels, depolarizes somatosensory neurons in response to cold. TRPM8 is also activated by the cooling agents menthol and icilin. When exposed to menthol or cold, TRPM8 behaves like many ligand-gated channels, exhibiting rapid activation followed by moderate Ca2+-dependent adaptation. In contrast, icilin activates TRPM8 with extremely variable latency followed by extensive desensitization, provided that calcium is present. Here, we show that, to achieve full efficacy, icilin requires simultaneous elevation of cytosolic Ca2+, either via permeation through TRPM8 channels or by release from intracellular stores. Thus, two stimuli must be paired to elicit full channel activation, illustrating the potential for coincidence detection by TRP channels. Determinants of icilin sensitivity map to a region of TRPM8 that corresponds to the capsaicin binding site on the noxious heat receptor TRPV1, suggesting a conserved mol. logic for gating of these thermosensitive channels by chemical agonists.
IT **36945-98-9**, Icilin
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(super-cooling agent icilin reveals a mechanism of coincidence detection by a temperature-sensitive TRP channel)
RN 36945-98-9 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)-

(9CI) (CA INDEX NAME)



REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:546400 CAPLUS
DOCUMENT NUMBER: 141:88219
TITLE: Compound delivery systems comprising a cooling compound such as menthol or icilin
INVENTOR(S): Appelqvist, Ingrid Anne Marie; Malone, Mark Emmett; Nandi, Asish
PATENT ASSIGNEE(S): Unilever PLC, UK; Unilever NV; Hindustan Lever Limited
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056332	A1	20040708	WO 2003-EP14179	20031210
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004151674	A1	20040805	US 2003-740252	20031218
PRIORITY APPLN. INFO.:			GB 2002-29811 A	20021220

OTHER SOURCE(S): MARPAT 141:88219

AB A composition comprising (a) from 0.005% to 0.5% by weight of a cooling compound; (b) from 0.1% to 10% by weight of an emulsifiable substance; (c) from 0.15% to 15% by weight of a surfactant; and (d) optionally up to 5% by weight, preferably from 0.05% to 5% by weight of a cosurfactant. The cooling compound is preferably icilin or menthol. The composition is to be used in toothpastes, mouthwashes, beverages, water ice, spreads, dressings or ice cream. For example, a fruit flavored tea beverage contained (by weight) sugar 7.2%, tea powder 0.14%, acids & salts 0.215%,

fruit juice & flavor 0.38%, Brij 96 0.15%, glycerol 0.05%, medium-chain triglycerides 0.1%, cooling active 0.005%, and water to 100%. It was found that using as cooling active, resp. menthol or 1-(2'-methoxyphenyl)-4-(3''-nitrophenyl)-1,2,3,6-tetrahydropyrimidin-2-one, ingestion in the form of the composition of the above example prolonged the cooling effect perceived, relative to the same amount of the cooling active alone.

IT **36945-90-1 36945-98-9**, Icilin
RL: COS (Cosmetic use); FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(dentifrices and food comprising cooling compound such as menthol or icilin)

RN 36945-90-1 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-methoxyphenyl)-4-(3-nitrophenyl)-(9CI) (CA INDEX NAME)



RN 36945-98-9 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:534237 CAPLUS
DOCUMENT NUMBER: 141:83606
TITLE: ANKTMI, a cold-activated TRP-like channel expressed in nociceptive neurons, and its cDNA from mouse and use thereof in drug screening
INVENTOR(S): Bevan, Stuart; Patapoutian, Ardem; Story, Gina M.
PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis Pharma GmbH; The Scripps Research Institute
SOURCE: PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE; English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004055054	A1	20040701	WO 2003-EP14403	20031217

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW

RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR

PRIORITY APPLN. INFO.: US 2002-434540P P 20021218

AB The methods and compns. of the invention are based on a method for measuring nociceptive responses in vertebrates, including humans and other mammals utilizing a newly discovered thermoreceptor belonging to the Transient Receptor Potential (TRP) family of non-selective cation channels that participates in thermosensation and pain. This receptor, designated ANKTMI, is associated with nociceptive pain, such as hyperalgesia. Accordingly, the invention provides isolated protein sequences of ANKTMI from mouse, human, Drosophila melanogaster, and cDNA sequence of mouse ANKTMI. ANKTM1 is a distant family member of TRP channels with very little amino acid similarity to TRPM8. ANKTM1 is characterized as a cold-activated channel with a lower activation temperature compared to the cold and menthol receptor, TRPM8. It is only detected in dorsal root ganglion, but not in normal tissue in rat. It is found to be coexpressed with TRPV1/VR1 (the capsaicin/heat receptor) but not TRPM8 in a subset of nociceptive sensory neurons. Consistent with the expression of ANKTM1, noxious cold-sensitive sensory neurons is identified to respond to capsaicin but not to menthol. Methods for identifying or screening agents that modulate nociception using ANKTM1 are also described.

IT **36945-98-9**, Icilin
RL: BSU (Biological study, unclassified); BIOL (Biological study) (ANKTMI expressing neuron in response to; ANKTMI, a cold-activated TRP-like channel expressed in nociceptive neurons, and its cDNA from mouse and use thereof in drug screening)

RN 36945-98-9 CAPLUS

CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:531298 CAPLUS

DOCUMENT NUMBER: 141:65083
TITLE: Use of a TRPM8-activating substance for the treatment of tumors
INVENTOR(S): Plath, Thomas; Reule, Matthias; Kaiser, Simone
PATENT ASSIGNEE(S): Metagen Pharmaceuticals GmbH, Germany; Lichtner, Rosemarie; Heiden Constanios-Velez, Esmeralda
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004054497	A2	20040701	WO 2003-DE4233	20031216
WO 2004054497	A3	20041223		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10259619	A1	20040708	DE 2002-10259619	20021218
PRIORITY APPLN. INFO.:			DE 2002-10259619 A	20021218

AB The invention discloses the use of a TRPM8-activating substance for producing a pharmaceutical composition for the treatment of tumors in which TRPM8 is overexpressed. Compds. of the invention include e.g. icilin.

IT **36945-98-9**, Icilin **36945-98-9D**, Icilin, derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TRPM8-activating substance for tumor treatment)

RN 36945-98-9 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)-(9CI) (CA INDEX NAME)



RN 36945-98-9 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)-(9CI) (CA INDEX NAME)



L9 ANSWER 6 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:514383 CAPLUS
DOCUMENT NUMBER: 141:68658
TITLE: TRPM8 activation by menthol, icilin, and cold is differentially modulated by intracellular pH
AUTHOR(S): Andersson, David A.; Chase, Henry W. N.; Bevan, Stuart
CORPORATE SOURCE: Novartis Institute for Medical Sciences, London, WC1E 6BN, UK
SOURCE: Journal of Neuroscience (2004), 24(23), 5364-5369
CODEN: JNRSDS; ISSN: 0270-6474
PUBLISHER: Society for Neuroscience
DOCUMENT TYPE: Journal
LANGUAGE: English

AB TRPM8 is a nonselective cation channel activated by cold and the cooling compds. menthol and icilin. Here, we have used electrophysiol. and the calcium-sensitive dye Fura-2 to study the effect of pH and interactions between temperature, pH, and the two chemical agonists menthol and icilin on TRPM8 expressed in Chinese hamster ovary cells. Menthol, icilin, and cold all evoked stimulus-dependent [Ca2+]i responses in standard physiol. solns. of pH 7.3. Increasing the extracellular [H+] from pH 7.3 to approx. pH 6 abolished responses to icilin and cold stimulation but did not affect responses to menthol. Icilin concentration-response curves were significantly shifted to the right when pH was lowered from 7.3 to 6.9, whereas those with menthol were unaltered in solns. of pH 6.1. When cells were exposed to solns. in the range of pH 8.1-6.5, the temperature threshold for activation was elevated at higher pH and depressed at lower pH. Superfusing cells with a low subactivating concentration of icilin or menthol elevated the threshold for cold activation at pH 7.4, but cooling failed to evoke [Ca2+]i responses at pH 6 in the presence of either agonist. In voltage-clamp expts. in which the intracellular pH was buffered to different levels, acidification reduced the current amplitude of icilin responses and shifted the threshold for cold activation to lower values with half-maximal inhibition at pH 7.2 and pH 7.6. The results demonstrate that the activation of TRPM8 by icilin and cold, but not menthol, is modulated by intracellular pH in the physiol. range. Furthermore, our data suggest that activation by icilin and cold involve a different mechanism to activation by menthol.

IT **36945-98-9**, Icilin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TRPM8 activation by menthol, icilin, and cold is differentially modulated by intracellular pH)
RN 36945-98-9 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:284591 CAPLUS
DOCUMENT NUMBER: 141:278
TITLE: Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay
AUTHOR(S): Behrendt, H.-J.; Germann, T.; Gillen, C.; Hatt, H.; Jostock, R.
CORPORATE SOURCE: Gruenenthal GmbH, Molecular Pharmacology, Aachen, 52099, Germany
SOURCE: British Journal of Pharmacology (2004), 141(4), 737-745
CODEN: BJPCBM; ISSN: 0007-1188
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English

AB TRPM8 (CMR1) is a Ca2+-permeable channel, which can be activated by low temps., menthol, eucalyptol and icilin. It belongs to the transient receptor potential (TRP) family, and therefore is related to vanilloid receptor type-1 (VR1, TRPV1). We tested whether substances which are structurally related to menthol, or which produce a cooling sensation, could activate TRPM8, and compared the responses of TRPM8 and VR1 to these ligands. The effects of 70 odorants and menthol-related substances on recombinant mouse TRPM8 (mTRPM8), expressed in HEK293 cells, were examined using a FLIPR assay. In all, 10 substances (linalool, geraniol, hydroxycitronellal, WS-3, WS-23,. FrescolatMGA, FrescolatML, PMD38, CoolactP and Cooling Agent 10) were found to be agonists. The EC50 values of the agonists defined their relative potencies: icilin (0.2 ± 0.1 μM) > FrescolatML (3.3 ± 1.5 μM) > WS-3 (3.7 ± 1.7 μM) (-)menthol (4.1 ± 1.3 μM) frescolatMAG (4.8 ± 1.1 μM) > cooling agent 10 (6 ± 2.2 μM) (+)menthol (14.4 ± 1.3 μM) > PMD38 (31 ± 1.1 μM) > WS-23 (44 ± 7.3 μM) > Coolact P (66 ± 20 μM) > geraniol (5.9 ± 1.6 mM) > linalool (6.7 ± 2.0 mM) > eucalyptol (7.7 ± 2.0 mM) > hydroxycitronellal (19.6 ± 2.2 mM). Known VR1 antagonists (BCTC, thio-BCTC and capsazepine) were also able to block the response of TRPM8 to menthol (IC50: 0.8 ± 1.0, 3.5 ± 1.1 and 18 ± 1.1 μM, resp.). The Ca2+ response of hVR1-transfected HEK293 cells to the endogenous VR1 agonist N-arachidonoyl-dopamine was potentiated by low pH. In contrast, menthol- and icilin-activated TRPM8 currents were suppressed by low pH. In conclusion, in the present study, we identified 10 new agonists and three antagonists of TRPM8. We found that, in contrast to VR1, TRPM8 is inhibited rather than potentiated by protons.

IT **36945-98-9**, Icilin

RL: PAC (Pharmacological activity); BIOL (Biological study)
(characterization of mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay)
RN 36945-98-9 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 8 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:267308 CAPLUS
DOCUMENT NUMBER: 140:303686
TITLE: Tetrahydropyrimidine-2-one derivatives and their uses, particularly for producing a cooling sensation, and application to oral and personal hygiene products and foodstuffs.
INVENTOR(S): Foster, Alison; Van der Logt, Cornelis Paul Erik; Tareilus, Erwin Werner
PATENT ASSIGNEE(S): Unilever PLC, UK; Unilever NV; Hindustan Lever Limited
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026840	A1	20040401	WO 2003-EP9566	20030826
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004067970	A1	20040408	US 2003-664367	20030917
PRIORITY APPLN. INFO.:			GB 2002-21697 A	20020918

OTHER SOURCE(S): MARPAT 140:303686

GI



I



II



III

AB Use of compds. I or their salts to produce a cooling sensation is disclosed [wherein: R1 and R2 = H, halo, OH, cyano, NO2, SH, CO, sulfone, carboxy, (un)substituted alkyl, alkenyl, alkoxy, alkylthio, aryl, aryloxy, arylthio, amino, siloxy, ester, or heterocyclic, with the proviso that R1 = 2-hydroxyphenyl, R2 = 3-nitrophenyl, i.e., icilin (II), is excluded]. II is a known cooling-sensation-producing compound with advantages over menthol, including greater potency and lower acute toxicity. Approx. 10 specific compds. are claimed. Claimed uses include toothpaste, mouthwash, beverages, ice cream, and confectionaries. For instance, compound III was prepared in 3 steps: (1) α-aminomethylation of 3-ClC6H4COMe with CH2(NMe2)2 (84%); (2) amine substitution of the dimethylamino group in the product by 2-aminophenol (40%); and (3) cyclocondensation of the obtained amino ketone 3-ClC6H4COCH2CH2NHC6H4OH-2.HCl with potassium cyanate to form the tetrahydropyrimidinone ring (41%). In a test for effects on cultured rat trigeminal neurons (measured by monitoring cellular Ca2+ levels), III had activity (35% vs. II) comparable to that of menthol (42% vs. II).

IT **36945-90-1**, 1-(2-Methoxyphenyl)-4-(3-nitrophenyl)-1,2,3,6-tetrahydropyrimidin-2-one **36945-95-6**, 1-(2-Hydroxyphenyl)-4-phenyl-1,2,3,6-tetrahydropyrimidin-2-one **36945-98-9**, 1-(2-Hydroxyphenyl)-4-(3-nitrophenyl)-1,2,3,6-tetrahydropyrimidin-2-one **333749-68-1**, 1-(2-Hydroxyphenyl)-4-(3-methoxyphenyl)-1,2,3,6-tetrahydropyrimidin-2-one **439121-50-3**, 1-(2-Methoxyphenyl)-4-(3-methoxyphenyl)-1,2,3,6-tetrahydropyrimidin-2-one **676364-22-0**, 1-Phenyl-4-(3-nitrophenyl)-1,2,3,6-tetrahydropyrimidin-2-one **676364-23-1**, 1-(2-Methoxyphenyl)-4-(3-chlorophenyl)-1,2,3,6-tetrahydropyrimidin-2-one **676364-24-2**, 1-(2-Methylphenyl)-4-(3-nitrophenyl)-1,2,3,6-tetrahydropyrimidin-2-one **676364-25-3**, 1-Phenyl-4-(3-chlorophenyl)-1,2,3,6-tetrahydropyrimidin-2-one **676364-26-4**, 1-Phenyl-4-(3-methoxyphenyl)-1,2,3,6-tetrahydropyrimidin-2-one **676364-27-5**

, 1-(2-Trifluoromethylphenyl)-4-(3-nitrophenyl)-1,2,3,6-tetrahydropyrimidin-2-one **676364-28-6**, 1-(2-Hydroxyphenyl)-4-(3-methylphenyl)-1,2,3,6-tetrahydropyrimidin-2-one
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); COS (Cosmetic use); FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(non-pharmaceutical cooling sensory agent; preparation and use of tetrahydropyrimidinone derivs. for producing a cooling sensation, and application to oral and personal hygiene products and foodstuffs)

RN 36945-90-1 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-methoxyphenyl)-4-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 36945-95-6 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 36945-98-9 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 333749-68-1 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 439121-50-3 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-methoxyphenyl)-4-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 676364-22-0 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-4-(3-nitrophenyl)-1-phenyl- (9CI) (CA INDEX NAME)



RN 676364-23-1 CAPLUS
CN 2(1H)-Pyrimidinone, 4-(3-chlorophenyl)-3,6-dihydro-1-(2-methoxyphenyl)-(9CI) (CA INDEX NAME)



RN 676364-24-2 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-methylphenyl)-4-(3-nitrophenyl)-(9CI) (CA INDEX NAME)



RN 676364-25-3 CAPLUS
CN 2(1H)-Pyrimidinone, 4-(3-chlorophenyl)-3,6-dihydro-1-phenyl- (9CI)

(CA INDEX NAME)



RN 676364-26-4 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-4-(3-methoxyphenyl)-1-phenyl- (9CI) (CA INDEX NAME)



RN 676364-27-5 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-4-(3-nitrophenyl)-1-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 676364-28-6 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-(3-methylphenyl)- (9CI) (CA INDEX NAME)



IT **36945-82-1P**, 1-(2-Hydroxyphenyl)-4-(3-chlorophenyl)-1,2,3,6-tetrahydropyrimidin-2-one
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); COS (Cosmetic use); FFD (Food or feed use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(non-pharmaceutical cooling sensory agent; preparation and use of tetrahydropyrimidinone derivs. for producing a cooling sensation, and application to oral and personal hygiene products and foodstuffs)

RN 36945-82-1 CAPLUS
CN 2(1H)-Pyrimidinone, 4-(3-chlorophenyl)-3,6-dihydro-1-(2-hydroxyphenyl)-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 9 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:972194 CAPLUS
DOCUMENT NUMBER: 140:24136
TITLE: Heterologous stimulus-gated ion channels TRPV1, TRPM8, and P2X2 and methods of using same
INVENTOR(S): Miesenbock, Gero A.; Zemelman, Boris V.
PATENT ASSIGNEE(S): Sloan-Kettering Institute for Cancer Research, USA
SOURCE: PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003102156	A2	20031211	WO 2003-US17448		20030602
WO 2003102156	A3	20041118			
WO 2003102156	B1	20050217			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 2004023203	A1	20040205	US 2003-452879		20030602
PRIORITY APPLN. INFO.:			US 2002-384670P	P	20020531
			US 2003-441452P	P	20030121

AB The invention claims methods and compns. to activate a genetically designated target cell (or population of target cells) artificially, in vivo or in vitro, by triggering of heterologous stimulus-gated ion channels. The stimulus-gated ion channels are suitably TRPV1, TRPM8, or purinoceptor P2X2. A stimulus which leads to opening or gating of the ion channel can be a phys. stimulus or a chemical stimulus. Phys.

stimuli can be provided by heat, or mech. force, while chemical stimuli can suitably be a ligand, such as capsaicin for TRPV1 or ATP for P2X2, or a 'caged ligand', for example a photolabile ligand derivative, in which case a phys. signal in the form of light is used to provide the chemical signal. The stimulus-gated ion channels may be expressed from transgenes under control of regulatable and/or cell type-specific promoter elements. In addition, reporter genes and their proteins may be used to mark the heterologous stimulus-gated ion channels or cells. Selective activation of the transgenic cell may be used for various applications including mapping of neuronal and neuroendocrine pathways, detection of diseased cells, and drug screening. Examples of the invention diagram lentiviral vectors and ROSA26 genomic targeting vectors for ion channel genes. The examples also show photostimulation by DMNB-capsaicin or DMNPE-ATP of transfected hippocampal neurons expressing TRPV1 or P2X2 resp.

IT **36945-98-9**, Icilin
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(activation of TRPM8; heterologous stimulus-gated ion channels and methods of using same)

RN 36945-98-9 CAPLUS

CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)-(9CI) (CA INDEX NAME)



L9 ANSWER 10 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:874970 CAPLUS
DOCUMENT NUMBER: 139:345942
TITLE: 1,2,3,6-Tetrahydropyrimidine-2-one compositions and therapeutic methods for pain and inflammation
INVENTOR(S): Wei, Edward T.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 9 pp., Cont.-in-part of U.S. Ser. No. 139,193.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003207904	A1	20031106	US 2002-232798	20020829
US 6743801	B2	20040601		
US 2003207851	A1	20031106	US 2002-139193	20020502
WO 2003092697	A1	20031113	WO 2003-GB1811	20030428

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,

LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG

EP 1503763 A1 20050209 EP 2003-718956 20030428
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,
PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.: US 2002-139193 A2 20020502

US 2002-191481 A 20020708

US 2002-232798 A 20020829

US 2002-233126 A 20020829

US 2002-267896 A 20021008

WO 2003-GB1811 W 20030428

OTHER SOURCE(S): MARPAT 139:345942

AB A therapeutic composition is provided that comprises a substituted 1,2,3,6-tetrahydropyrimidine-2-one sensory nerve receptor agonist in a therapeutically effective amount The sensory nerve receptor agonist is 1-[R1-phenyl]-4-[R2-phenyl]-1,2,3,6-tetrahydropyrimidine-2-one (R1 = OH, Cl, F, alkyl, acetoxy, CF3; R2 = nitro, Cl, F, alkyl, CF3). Therapeutic compns. of the invention reduce pain, itch, and a sense of discomfort, when formulated for topical delivery to the human lips, mouth, and to the anorectal area.

IT **36945-98-9 36945-98-9D**, analogs
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetrahydropyrimidinone derivative compns. and therapeutic methods for pain and inflammation)

RN 36945-98-9 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)-(9CI) (CA INDEX NAME)



RN 36945-98-9 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)-(9CI) (CA INDEX NAME)



L9 ANSWER 11 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:874969 CAPLUS
DOCUMENT NUMBER: 139:345959
TITLE: 1,2,3,6-Tetrahydropyrimidine-2-one compositions and therapeutic methods for sexual disfunction
INVENTOR(S): Wei, Edward T.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 8 pp., Cont.-n-part of U.S. Ser. No. 139,193.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003207903	A1	20031106	US 2002-191481	20020708
US 2003207851	A1	20031106	US 2002-139193	20020502
WO 2003092697	A1	20031113	WO 2003-GB1811	20030428
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1503763	A1	20050209	EP 2003-718956	20030428
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.:

US 2002-139193	A2	20020502
US 2002-191481	A	20020708
US 2002-232798	A	20020829
US 2002-233126	A	20020829
US 2002-267896	A	20021008
WO 2003-GB1811	W	20030428

OTHER SOURCE(S): MARPAT 139:345959
AB A therapeutic composition is provided that comprises a substituted

1,2,3,6-tetrahydropyrimidine-2-one sensory nerve receptor agonist in a therapeutically effective amount The sensory nerve receptor agonist is 1-[R1-phenyl]-4-[R2-phenyl]-1,2,3,6-tetrahydropyrimidine-2-one (R1 = OH, Cl, F, alkyl, acetoxy, CF3; R2 = nitro, Cl, F, -alkyl, CF3). Therapeutic compns. of the invention elicit soothing, cooling, and stimulatory effects when formulated for topical delivery to human sexual organs and to anorectal areas of the body and are useful to alleviate dysfunction in sexual response and intercourse for both men and women.

IT **36945-98-9 36945-98-9D**, analogs
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetrahydropyrimidinone compns. and therapeutic methods for sexual disfunction)

RN 36945-98-9 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 36945-98-9 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



L9 ANSWER 12 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:874964 CAPLUS
DOCUMENT NUMBER: 139:354482
TITLE: Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
INVENTOR(S): Wei, Edward T.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 13 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 2003207851	A1	20031106	US 2002-139193	20020502
US 2003207903	A1	20031106	US 2002-191481	20020708
US 2003207904	A1	20031106	US 2002-232798	20020829
US 6743801	B2	20040601		
US 2003206873	A1	20031106	US 2002-233126	20020829
US 2003206866	A1	20031106	US 2002-267896	20021008
WO 2003092697	A1	20031113	WO 2003-GB1811	20030428

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1503763	A1	20050209	EP 2003-718956	20030428

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.:	US 2002-139193	A2 20020502
	US 2002-191481	A 20020708
	US 2002-232798	A 20020829
	US 2002-233126	A 20020829
	US 2002-267896	A 20021008
	WO 2003-GB1811	W 20030428

OTHER SOURCE(S): MARPAT 139:354482

AB A therapeutic composition is provided that comprises a 1,2,3,6-tetrahydropyrimidine-2-one derivative cold receptor agonist in a therapeutically effective amount and preferably further comprises one or more pharmaceutically active drugs such as an anti-inflammatory glucocorticosteroid, a sympathomimetic amine decongestant, an antihistamine, a local anesthetic, menthol or a menthol analog, and mixts. thereof. Therapeutic compns. of the invention elicit long-lasting cooling or soothing, particularly when formulated for delivery to suppress the sensations of itch and pain, such as for delivery to inflamed skin, to the mucous membranes of the anogenital areas, and to the enteric mucosa. For example, a male subject with an abrasion on his finger of about 1 cm2 received 0.8 mg of icilin applied directly to the wound with a swab stick. The dull pain previously present at the wound site began to feel cold and the pain was lessened.

IT **36945-98-9**, Icilin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical compns. containing 1,2,3,6-tetrahydropyrimidine-2-one derivs. and other actives for antipruritic effects)

RN 36945-98-9 CAPLUS

CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



L9 ANSWER 13 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:874765 CAPLUS
DOCUMENT NUMBER: 139:345928
TITLE: 1,2,3,6-Tetrahydropyrimidine-2-one compositions and therapeutic methods for gastrointestinal dysfunction
INVENTOR(S): Wei, Edward T.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 8 pp., Cont.-in-part of U.S. Ser. No. 139,193.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003206873	A1	20031106	US 2002-233126	20020829
US 2003207851	A1	20031106	US 2002-139193	20020502
WO 2003092697	A1	20031113	WO 2003-GB1811	20030428
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1503763	A1	20050209	EP 2003-718956	20030428
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.:

US 2002-139193	A2	20020502
US 2002-191481	A	20020708
US 2002-232798	A	20020829
US 2002-233126	A	20020829
US 2002-267896	A	20021008
WO 2003-GB1811	W	20030428

OTHER SOURCE(S): MARPAT 139:345928
AB A therapeutic composition is provided that comprises a substituted

1,2,3,6-tetrahydropyrimidine-2-one sensory nerve receptor agonist in a therapeutically effective amount The sensory nerve receptor agonist is 1-[R1-phenyl]-4-[R2-phenyl]-1,2,3,6-tetrahydropyrimidine-2-one (R1 = OH, Cl, F, alkyl, acetoxy, CF3; R2 = nitro, Cl, F, alkyl, CF3). Therapeutic compns. of the invention reduce pain, a sense of abdominal distension, tenesmus, and abnormal bowel function when formulated for oral delivery to human gastrointestinal tract and are useful to alleviate gastrointestinal dysfunction.

IT **36945-98-9 36945-98-9D**, analogs and sugar conjugates
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetrahydropyrimidinone derivative compns. and therapeutic methods for gastrointestinal dysfunction)

RN 36945-98-9 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 36945-98-9 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



L9 ANSWER 14 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:874763 CAPLUS
DOCUMENT NUMBER: 139:354472
TITLE: Inhalable compositions containing 1,2,3,6-tetrahydropyrimidine-2-one derivatives and other actives for upper airway breathing disorders
INVENTOR(S): Wei, Edward T.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 10 pp., Cont.-in-part of U.S. Ser. No. 139,193.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 2003206866	A1	20031106	US 2002-267896	20021008
US 2003207851	A1	20031106	US 2002-139193	20020502
WO 2003092697	A1	20031113	WO 2003-GB1811	20030428

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1503763	A1	20050209	EP 2003-718956	20030428

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.:	US 2002-139193	A2 20020502
	US 2002-191481	A 20020708
	US 2002-232798	A 20020829
	US 2002-233126	A 20020829
	US 2002-267896	A 20021008
	WO 2003-GB1811	W 20030428

OTHER SOURCE(S): MARPAT 139:354472

AB A therapeutic composition is provided that comprises a 1,2,3,6-tetrahydropyrimidine-2-one derivative cold receptor agonist in a therapeutically effective amount Therapeutic compns. of the invention when formulated for delivery to the mucous membranes of the nose and throat alleviate the sensations of airway obstruction and provide symptomatic relief of upper airway breathing disorders. A 10 % icilin dissolved in propylene glycol was mixed 1:5 with Ayr Saline Nasal Mist to yield a 2 % concentration The icilin-saline spray mist was applied intranasally to a subject with nasal congestion from seasonal allergic rhinitis. Sensations of coolness were experienced and the sense of nasal obstruction was relieved.

IT **36945-98-9**, Icilin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhalable compns. containing 1,2,3,6-tetrahydropyrimidine-2-one derivs. and other actives for upper airway breathing disorders)

RN 36945-98-9 CAPLUS

CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



L9 ANSWER 15 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:610589 CAPLUS
DOCUMENT NUMBER: 139:177515
TITLE: The cold and menthol receptor CMR1 playing a role in cold perception and the identification of chemical modulators of cold sensation
INVENTOR(S): Julius, David; McKemy, David D.; Neuhausser, Werner M.
PATENT ASSIGNEE(S): The Regents of the University of California, USA
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003064602	A2	20030807	WO 2003-US2318	20030127
WO 2003064602	A3	20040219		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003219834	A1	20031127	US 2003-352724	20030127
EP 1474516	A2	20041110	EP 2003-735008	20030127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.:

US 2002-351974P	P	20020125
US 2002-355037P	P	20020207
WO 2003-US2318	W	20030127

AB A member of the transient receptor potential family that is important in the reception of cold sensations and comparable sensations induced by chems. such as menthol, the cold and menthol receptor CMR1, is identified in the trigeminal nerves of rats. CDNAs encoding the receptor are cloned and characterized. The invention further relates to methods for identifying and using agents that modulate cold responses and pain responses stimulated by cold via modulation of CMR1

and CMR1-related signal transduction. CMR1 modulators may also be used in cosmetics and foods.

IT **36945-98-9**, AG-3-5
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(induction of cold sensations by; cold and menthol receptor CMR1 playing role in cold perception and identification of chemical modulators of cold sensation)

RN 36945-98-9 CAPLUS

CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)-(9CI) (CA INDEX NAME)



L9 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:230149 CAPLUS

DOCUMENT NUMBER: 137:44681

TITLE: Identification of a cold receptor reveals a general role for TRP channels in thermosensation

AUTHOR(S): McKemy, David D.; Neuhausser, Werner M.; Julius, David

CORPORATE SOURCE: Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA, 94143-0450, USA

SOURCE: Nature (London, United Kingdom) (2002), 416(6876), 52-58
CODEN: NATUAS; ISSN: 0028-0836

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The cellular and mol. mechanisms that enable us to sense cold are not well understood. Insights into this process have come from the use of pharmacol. agents, such as menthol, that elicit a cooling sensation. Here we have characterized and cloned a menthol receptor from trigeminal sensory neurons that is also activated by thermal stimuli in the cool to cold range. This cold- and menthol-sensitive receptor, CMR1, is a member of the TRP family of excitatory ion channels, and we propose that it functions as a transducer of cold stimuli in the somatosensory system. These findings, together with our previous identification of the heat-sensitive channels VR1 and VRL-1, demonstrate that TRP channels detect temps. over a wide range and are the principal sensors of thermal stimuli in the mammalian peripheral nervous system.

IT **36945-98-9**, AG-3-5
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(identification of receptor sensitive to compds. producing sensation of cold reveals general role for TRP channels in thermosensation)

RN 36945-98-9 CAPLUS

CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 17 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:298390 CAPLUS
DOCUMENT NUMBER: 124:343323
TITLE: Preparation of tetrahydropyrimidinone derivatives as pesticides
INVENTOR(S): Mita, Takeshi; Numata, Akira; Ishii, Shigeru; Kudo, Masaki; Inoe, Yoichi; Myake, Toshiro
PATENT ASSIGNEE(S): Nissan Chemical Ind Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 36 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08027120	A2	19960130	JP 1994-157053	19940708
PRIORITY APPLN. INFO.:			JP 1994-157053	19940708

OTHER SOURCE(S): MARPAT 124:343323
GI



I



II

AB Tetrahydropyrimidinones [I; R1, R2 = H, C1-6 alkyl, C3-6 cycloalkyl; X1, X2 = halo, C1-4 alkyl, C1-4 alkoxy; Y = halo, C1-6 alkyl, C2-6 alkenyl; Z = O, S, NH; l = 0-4; m = 1-5], effective insecticides and miticides with no harmful effects on mammals and fish, are prepared A mixture of amine salt II and KOCN in HOAc was heated with stirring at 60° to give 87.1% I [R1 = R2 = H, X1 = F, (X2)l = 6-F, (Y)m = 4-Cl, Z = O], which killed 100% brown rice planthoppers at 1000 ppm.

IT **176523-53-8P 176523-54-9P 176523-55-0P 176523-56-1P 176523-59-4P 176523-60-7P 176523-61-8P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetrahydropyrimidinone derivs. as pesticides)

RN 176523-53-8 CAPLUS

CN 2(1H)-Pyrimidinone, 4-(2-chlorophenyl)-1-(4-chlorophenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 176523-54-9 CAPLUS

CN 2(1H)-Pyrimidinone, 4-(2-chlorophenyl)-3,6-dihydro-1-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 176523-55-0 CAPLUS

CN 2(1H)-Pyrimidinone, 1-(4-chlorophenyl)-4-(2,6-difluorophenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 176523-56-1 CAPLUS
CN 2(1H)-Pyrimidinone, 4-(2,6-difluorophenyl)-3,6-dihydro-1-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 176523-59-4 CAPLUS
CN 2(1H)-Pyrimidinone, 4-(2-fluorophenyl)-3,6-dihydro-1-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 176523-60-7 CAPLUS
CN 2(1H)-Pyrimidinone, 1-(4-chlorophenyl)-4-(2-fluorophenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 176523-61-8 CAPLUS
CN 2(1H)-Pyrimidinone, 1-(3,4-dichlorophenyl)-4-(2,6-difluorophenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



L9 ANSWER 18 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1983:551925 CAPLUS
DOCUMENT NUMBER: 99:151925
TITLE: AG-3-5: a chemical producing sensations of cold
AUTHOR(S): Wei, E. T.; Seid, D. A.
CORPORATE SOURCE: Sch. Public Health, Univ. California, Berkeley, CA, 94720, USA
SOURCE: Journal of Pharmacy and Pharmacology (1983), 35(2), 110-12
CODEN: JPPMAB; ISSN: 0022-3573
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Ingestion of 0.1 mg AG-3-5 (I) [**36945-98-9**] by humans selectively acted on peripheral cold receptors in the upper alimentary tract to produce sensations of cold which lasted for 15-30 min. Mild sensations of coolness were also experienced on the cheeks and inner surfaces of the arms and legs. Upon topical application, I did not readily penetrate the intact skin surface to reach cold receptors in the epidermal basement membrane. I was less toxic than (-)-menthol [2216-51-5] to rats. I also lacked the odor and flavor of menthol.

IT **36945-98-9**
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(cold sensations induced by and toxicity of, in humans and laboratory animals)

RN 36945-98-9 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



L9 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1983:416114 CAPLUS
DOCUMENT NUMBER: 99:16114
TITLE: AG-3-5: a chemical which produces sensations of cold
AUTHOR(S): Wei, Eddie T.
CORPORATE SOURCE: Sch. Public Health, Univ. California, Berkeley,

CA, 94720, USA
SOURCE: Environ., Drugs Thermoregul., Int. Symp. Pharmacol. Thermoregul., 5th (1983), Meeting Date 1982, 183-6. Editor(s): Lomax, Peter; Schoenbaum, Eduard. Karger: Basel, Switz.
CODEN: 49SGAL
DOCUMENT TYPE: Conference
LANGUAGE: English
GI



I

AB The pharmacol. of the tetrahydropyrimidine-2-one derivative AG-3-5 (I) [**36945-98-9**] was evaluated in rats and humans in comparison with menthol. I (1 mg/kg, i.p.) produced wet shakes in rats within 2 min of administration; the ED50 for shaking was .apprx.0.18 mg/kg. Injections of menthol (125 mg/kg) also produced shaking, the ED50 being 35 mg/kg. I showed low acute toxicity when administered orally or i.p. to rats at doses up to 1.5 g/kg. The mutagenic potency of I was also low. In a human subject, the application of I to the dorsal surface of the tongue produced sensations of cold primarily in the upper alimentary tract. Application of I to the dorsal surface of the forearm, however, produced no local or systemic sensations of cold. Apparently, I does not readily penetrate the intact skin surface. Thus I, like menthol, can selectively act on peripheral cold receptors in the upper alimentary tract to produce sensations of cold in man. These properties of I suggest some potential pharmacol. applications, e.g. I may be useful in counteracting the pain of heat or burns. Also, I may be useful as a tool in investigating the chemical basis of temperature perception.

IT **36945-98-9**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. of, cold sensation in)

RN 36945-98-9 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



L9 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1981:202242 CAPLUS

DOCUMENT NUMBER: 94:202242
TITLE: Pharmacological aspects of shaking behavior produced by TRH, AG-3-5, and morphine withdrawal
AUTHOR(S): Wei, E. T.
CORPORATE SOURCE: Sch. Public Health, Univ. California, Berkeley, CA, 94720, USA
SOURCE: Federation Proceedings (1981), 40(5), 1491-6
CODEN: FEPRA7; ISSN: 0014-9446
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
GI



I



II

AB A review with 32 refs. of the pharmacol. of shaking behavior induced by TRH [24305-27-9], AG-3-5 (I) [**36945-98-9**] and morphine (II) [16206-77-2] withdrawal. Agents that inhibit shaking are also reviewed.

IT **36945-98-9**
RL: BIOL (Biological study)
(behavior response to, morphine withdrawal in relation to)

RN 36945-98-9 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



L9 ANSWER 21 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1978:499978 CAPLUS
DOCUMENT NUMBER: 89:99978
TITLE: Lysergic acid diethylamide antagonizes shaking induced in rats by five chemically different compounds
AUTHOR(S): Cowan, Alan; Watson, Trevor
CORPORATE SOURCE: Dep. Pharmacol., Reckitt and Colman, Hull, UK
SOURCE: Psychopharmacology (Berlin, Germany) (1978), 57(1), 43-6

CODEN: PSCHDL; ISSN: 0033-3158
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Thyrotropin-releasing hormone (TRH) [24305-27-9], sodium valproate [1069-66-5], AG 35 [1-(2-hydroxyphenyl)-4-(3-nitrophenyl)-1,2,3,6-tetrahydropyrimidin-2-one] [**36945-98-9**], RX 336M maleate (I maleate) [67068-70-6], and Sgd 8473 [α-[(4-chlorobenzylidene)aminooxy]isobutyric acid] [59079-16-2] each induced repetitive shaking of the body of rats after i.p. injection. This action of the 5 diverse chems. appears to be subserved by a common pharmacol. component, because pretreatment with d-lysergic acid diethylamide tartrate [17676-08-3] (0.03-1.0 mg/kg01, s.c.) attenuated the shaking behavior in a dose-related manner, and cross tolerance was found between RX 336M and TRH, sodium valproate, and AG 35.

IT **36945-98-9**
RL: BIOL (Biological study)
(wet-dog shaking behavior from, LSD antagonism of)

RN 36945-98-9 CAPLUS

CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)-(9CI) (CA INDEX NAME)



L9 ANSWER 22 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1977:37572 CAPLUS
DOCUMENT NUMBER: 86:37572
TITLE: Chemical stimulants of shaking behavior
AUTHOR(S): Wei, Eddie T.
CORPORATE SOURCE: Sch. Public Health, Univ. California, Berkeley, CA, USA
SOURCE: Journal of Pharmacy and Pharmacology (1976), 28(9), 722-4
CODEN: JPPMAB; ISSN: 0022-3573
DOCUMENT TYPE: Journal
LANGUAGE: English

GI



I

AB AG-3-5 (I) [**36945-98-9**] (0.12-8.0 mg/kg) induced 'wet dog shaking' behavior in various mammals within 2 min of injection and the duration but not the frequency of the shaking was dose-dependent. In rats, haloperidol [52-86-8] and perphenazine-HCl [23221-95-6] (2 and 5 mg/kg resp., s.c.) attenuated the shaking response to I (8 mg/kg i.p.), and morphine sulfate [64-31-3], (±) methadone-HCl [125-56-4], and clonidine-HCl [4205-91-8] (10, 5, and 1 mg/kg resp., s.c.) suppressed the effects of I. The duration of Na pentobarbitone anesthesia was shortened by I treatment.

IT **36945-98-9**
RL: BIOL (Biological study)
(shaking behavior from, neuroleptics and opiates effect on)

RN 36945-98-9 CAPLUS

CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



L9 ANSWER 23 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1972:405510 CAPLUS

DOCUMENT NUMBER: 77:5510

TITLE: 1,2,3,6-Tetrahydro-2-pyrimidinones

INVENTOR(S): Podesva, Ctirad; Do Nascimento, Jose

PATENT ASSIGNEE(S): Delmar Chemicals Ltd.

SOURCE: Ger. Offen., 59 pp.
CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2142385	A	19720302	DE 1971-2142385	19710824
DE 2142385	B2	19750828		
DE 2142385	C3	19760408		
US 3821221	A	19740628	US 1970-66872	19700825
CA 940129	A1	19740115	CA 1971-121068	19710823
PRIORITY APPLN. INFO.:			US 1970-66872 A	19700825

GI For diagram(s), see printed CA Issue.

AB Tetrahydropyrimidinones including I (R = NO2, Br, Cl, I, CF3, CN) and their esters with C2-11 carboxylic acids are central nervous system depressants. -Adamantyl-4-(3-nitrophenyl-1,2,3,6-tetrahydro-2-pyrimidinone was a central nervous system stimulant. I were prepared by treating o-HOC6H4-NHCH2CH2COC6H4R-m (II) with KOCN. Thus I (R = NO2) was obtained by treating Et2NCH2CH2COC6H4NO2-m with o-HOC6H4NH2 to give II (R = NO2), whose hydrochloride was then treated with KOCN.

IT **36945-75-2P 36945-76-3P 36945-79-6P**
36945-82-1P 36945-84-3P 36945-86-5P
36945-90-1P 36945-92-3P 36945-95-6P
36945-98-9P 36950-53-5P 36950-54-6P
36950-55-7P 36950-56-8P 36950-57-9P
36950-58-0P 36950-59-1P 36950-60-4P
36950-61-5P 36950-62-6P 36950-63-7P
36950-64-8P 36950-65-9P 36950-67-1P
36950-70-6P 36950-71-7P 36950-72-8P
36950-73-9P 37053-56-8P 37449-25-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 36945-75-2 CAPLUS

CN Benzonitrile, 3-[1,2,3,6-tetrahydro-1-(2-hydroxyphenyl)-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 36945-76-3 CAPLUS

CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 36945-79-6 CAPLUS

CN 2(1H)-Pyrimidinone, 3,4-dihydro-3-(2-hydroxyphenyl)-6-(3-iodophenyl)-

(9CI) (CA INDEX NAME)



RN 36945-82-1 CAPLUS
CN 2(1H)-Pyrimidinone, 4-(3-chlorophenyl)-3,6-dihydro-1-(2-hydroxyphenyl)-
(9CI) (CA INDEX NAME)



RN 36945-84-3 CAPLUS
CN 2(1H)-Pyrimidinone, 4-(3-bromophenyl)-3,6-dihydro-1-(2-hydroxyphenyl)-
(9CI) (CA INDEX NAME)



RN 36945-86-5 CAPLUS
CN Benzoic acid, 2-[3,6-dihydro-4-(3-nitrophenyl)-2-oxo-1(2H)-
pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 36945-90-1 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-methoxyphenyl)-4-(3-nitrophenyl)-
(9CI) (CA INDEX NAME)



RN 36945-92-3 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-(4-nitrophenyl)-(9CI) (CA INDEX NAME)



RN 36945-95-6 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 36945-98-9 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)-(9CI) (CA INDEX NAME)



RN 36950-53-5 CAPLUS
CN Carbonic acid, 2-[4-(3-bromophenyl)-3,6-dihydro-2-oxo-1(2H)-pyrimidinyl]phenyl ethyl ester (9CI) (CA INDEX NAME)



RN 36950-54-6 CAPLUS
CN Benzoic acid, 3,4,5-trimethoxy-, 2-[4-(4-bromophenyl)-3,6-dihydro-2-oxo-1(2H)-pyrimidinyl]phenyl ester (9CI) (CA INDEX NAME)



RN 36950-55-7 CAPLUS
CN 2(1H)-Pyrimidinone, 4-(3-bromophenyl)-3,6-dihydro-1-[2-(1-oxopropoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 36950-56-8 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[2-(acetyloxy)phenyl]-4-(3-bromophenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 36950-57-9 CAPLUS
CN Benzoic acid, 3,4,5-trimethoxy-, 2-[3,6-dihydro-4-(4-nitrophenyl)-2-oxo-1(2H)-pyrimidinyl]phenyl ester (9CI) (CA INDEX NAME)



RN 36950-58-0 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[2-(benzoyloxy)phenyl]-3,6-dihydro-4-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 36950-59-1 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[2-(acetyloxy)phenyl]-3,6-dihydro-4-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 36950-60-4 CAPLUS
CN Carbonic acid, 2-[3,6-dihydro-4-(3-nitrophenyl)-2-oxo-1(2H)-pyrimidinyl]phenyl ethyl ester (9CI) (CA INDEX NAME)



RN 36950-61-5 CAPLUS
CN Butanoic acid, 3-methyl-, 2-[3,6-dihydro-4-(3-nitrophenyl)-2-oxo-1(2H)-pyrimidinyl]phenyl ester (9CI) (CA INDEX NAME)



RN 36950-62-6 CAPLUS
CN Hexanoic acid, 2-ethyl-, 2-[3,6-dihydro-4-(3-nitrophenyl)-2-oxo-1(2H)-pyrimidinyl]phenyl ester (9CI) (CA INDEX NAME)



RN 36950-63-7 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[2-(benzoyloxy)phenyl]-3,6-dihydro-4-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 36950-64-8 CAPLUS
CN Butanoic acid, 2-[3,6-dihydro-4-(3-nitrophenyl)-2-oxo-1(2H)-pyrimidinyl]phenyl ester (9CI) (CA INDEX NAME)



RN 36950-65-9 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-4-(3-nitrophenyl)-1-[2-(1-oxopropoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 36950-67-1 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[2-(acetyloxy)phenyl]-3,6-dihydro-4-phenyl- (9CI) (CA INDEX NAME)



RN 36950-70-6 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-4-(3-iodophenyl)-1-[2-(1-oxopropoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 36950-71-7 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[2-(acetyloxy)phenyl]-3,6-dihydro-4-(3-iodophenyl)- (9CI) (CA INDEX NAME)



RN 36950-72-8 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[2-(acetyloxy)phenyl]-4-(3-chlorophenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 36950-73-9 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 37053-56-8 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[2-(acetyloxy)phenyl]-3,6-dihydro-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 37449-25-5 CAPLUS
CN 10-Undecenoic acid, 2-[3,6-dihydro-4-(3-nitrophenyl)-2-oxo-1(2H)-pyrimidinyl]phenyl ester (9CI) (CA INDEX NAME)



L9 ANSWER 24 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1972:14479 CAPLUS
DOCUMENT NUMBER: 76:14479
TITLE: Pyrimidines. XXVIII. Formation of substituted 2-oxopyrimidines from β-(N-phenylureido) ketones
AUTHOR(S): Mamaev, V. P.; Nikol'skaya, G. S.; Lyubimova, E. N.
CORPORATE SOURCE: Novosib. Inst. Org. Khim., Novosibirsk, USSR
SOURCE: Izvestiya Sibirskogo Otdeleniya Akademii Nauk SSSR, Seriya Khimicheskikh Nauk (1971), (2), 86-90
CODEN: IZSKAB; ISSN: 0002-3426
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI For diagram(s), see printed CA Issue.
AB RCOCH2CHR1NHPh (R = Me, Ph; R1 = H, Ph) condensed with R2NCO (R2 = H, Me, Ph) in HOAc or C6H6 to give the corresponding RCOCH2CHR1NPhCONHR2 (I) in 36-72% yield. I (R2 = H, Me) cyclized under the reaction conditions, forming the corresponding substituted 2-oxo-1,2,3,4-tetrahydropyrimidines (II) in 30-60% yield.
IT **34954-19-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 34954-19-3 CAPLUS
CN 2(1H)-Pyrimidinone, 3,6-dihydro-1,4-diphenyl- (9CI) (CA INDEX NAME)



E1 THROUGH E47 ASSIGNED

FILE 'REGISTRY' ENTERED AT 12:14:33 ON 30 MAR 2005
L10 47 SEA FILE=REGISTRY ABB=ON PLU=ON (36945-98-9/BI OR 36945-90-1/BI OR 36945-82-1/BI OR 36945-95-6/BI OR 176523-53-8/BI OR 176523-54-9/BI OR 176523-55-0/BI OR 176523-56-1/BI OR 176523-59-4/BI OR 176523-60-7/BI OR 176523-61-8/BI OR 333749-68-1/BI OR 34954-19-3/BI OR 36945-75-2/BI OR 36945-76-3/BI OR 36945-79-6/BI OR 36945-84-3/BI OR 36945-86-5/BI OR 36945-92-3/BI OR 36950-53-5/BI OR 36950-54-6/BI OR 36950-55-7/BI OR 36950-56-8/BI OR 36950-57-9/BI OR 36950-58-Q/BI OR 36950-59-1/BI OR 36950-60-4/BI OR 36950-61-5/BI OR

36950-62-6/BI OR 36950-63-7/BI OR 36950-64-8/BI OR
36950-65-9/BI OR 36950-67-1/BI OR 36950-70-6/BI OR
36950-71-7/BI OR 36950-72-8/BI OR 36950-73-9/BI OR
37053-56-8/BI OR 37449-25-5/BI OR 439121-50-3/BI OR
676364-22-0/BI OR 676364-23-1/BI OR 676364-24-2/BI OR
676364-25-3/BI OR 676364-26-4/BI OR 676364-27-5/BI OR
676364-28-6/BI)

FILE 'CAOLD' ENTERED AT 12:14:51 ON 30 MAR 2005
L11 0 S L10

FILE 'USPATFULL' ENTERED AT 12:14:56 ON 30 MAR 2005
L12 9 S L10

L12 ANSWER 1 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2004:196371 USPATFULL
TITLE: Compound delivery systems
INVENTOR(S): Appelqvist, Ingrid Anne Marie, Vlaardingen, NETHERLANDS
Malone, Mark Emmett, Bedford, UNITED KINGDOM
Nandi, Asish, Bedford, UNITED KINGDOM
PATENT ASSIGNEE(S): Unilever Home & Personal Care USA, Division of Conopco, Inc. (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004151674	A1	20040805	
APPLICATION INFO.:	US 2003-740252	A1	20031218	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2002-29811	20021220

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: UNILEVER, PATENT DEPARTMENT, 45 RIVER ROAD, EDGEWATER, NJ, 07020
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 532
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A composition comprising

(a) from 0.005% to 0.5% by weight of a cooling compound;

(b) from 0.1% to 10% by weight of an emulsifiable substance;

(c) from 0.15% to 15% by weight of a surfactant;

(d) optionally up to 5% by weight, preferably from 0.05% to 5% by weight of a cosurfactant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 2 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2004:88993 USPATFULL
TITLE: Novel compounds and their uses
INVENTOR(S): Foster, Alison Jane, Bebington, UNITED KINGDOM
Van Der Logt, Cornelius Paul Erik, Vlaardingen, NETHERLANDS

	Tareilus, Erwin Werner, Vlaardingen, NETHERLANDS
PATENT ASSIGNEE(S):	Unilever Home & Personal Care USA, Division of Conopco, Inc. (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004067970	A1	20040408	
APPLICATION INFO.:	US 2003-664367	A1	20030917	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2002-21697	20020918

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	UNILEVER, PATENT DEPARTMENT, 45 RIVER ROAD, EDGEWATER, NJ, 07020
NUMBER OF CLAIMS:	33
EXEMPLARY CLAIM:	1
LINE COUNT:	639

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Use of a compound according to Formula [I]: ##STR1##

or a salt thereof to produce a cooling sensation, wherein R.sup.1 and R.sup.2 are independently selected from hydrogen or halogen atoms; hydroxy, cyano, nitro, mercapto, carbonyl, sulfone and carboxy groups: or optionally substituted alkyl, alkenyl, alkoxy, alkylthio, aryl, aryloxy, arylthio, amino, siloxy, ester and heterocyclic groups, with the proviso that when R.sup.1 is 2-hydroxyphenyl, R.sup.2 is other than 3-nitrophenyl.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 3 OF 9 USPATFULL on STN

ACCESSION NUMBER:	2004:31065 USPATFULL
TITLE:	Heterologous stimulus-gated ion channels and methods of using same
INVENTOR(S):	Miesenbock, Gero, New York, NY, UNITED STATES Zemelman, Bosis, New York, NY, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004023203	A1	20040205	
APPLICATION INFO.:	US 2003-452879	A1	20030602	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-384670P	20020531 (60)
	US 2003-441452P	20030121 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	OPPEDAHL AND LARSON LLP, P O BOX 5068, DILLON, CO, 80435-5068
NUMBER OF CLAIMS:	65
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	9 Drawing Page(s)
LINE COUNT:	2492

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compositions to activate a genetically designated target cell (or population of target cells) artificially, in vivo or in

vitro, employ triggering of heterologous stimulus-gated ion channels to activate the cells. The stimulus-gated ion channels are suitably TRPV1, TRPM8 or P2X.sub.2. A stimulus which leads to opening or "gating" of the ion channel can be a physical stimulus or a chemical stimulus. Physical stimuli can be provided by heat, or mechanical force, while chemical stimuli can suitably be a ligand, such as capsaicin for TRPV1 or ATP for P2X.sub.2, or a "caged ligand," for example a photolabile ligand derivative, in which case a physical signal in the form of light is used to provide the chemical signal. Selective activation of the cell may be used for various applications including neuronal and neuroendocrine mapping and drug screening.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 4 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2003:312237 USPATFULL
TITLE: Methods of modulating cold sensory perception
INVENTOR(S): Julius, David, San Francisco, CA, UNITED STATES
McKemy, David D., Livermore, CA, UNITED STATES
Neuhausser, Werner M., San Francisco, CA, UNITED STATES
PATENT ASSIGNEE(S): The Regents of the University of California (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003219834	A1	20031127	
APPLICATION INFO.:	US 2003-352724	A1	20030127	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-355037P	20020207	(60)
	US 2002-351974P	20020125	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 73
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 3483
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to regulation of cold sensation and pain. More particularly, the present invention is directed to nucleic acids encoding a member of the transient regulatory protein family, CMR1, which is involved in modulation of the perception of cold sensations and pain. The invention further relates to methods for identifying and using agents that modulate cold responses and pain responses stimulated by cold via modulation of CMR1 and CMR1-related signal transduction.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 5 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2003:294886 USPATFULL
TITLE: 1,2,3,6-tetrahydropyrimidine-2-one compositions and therapeutic methods therewith for pain and

inflammation
INVENTOR(S): Wei, Edward T., Berkeley, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003207904	A1	20031106
	US 6743801	B2	20040601
APPLICATION INFO.:	US 2002-232798	A1	20020829 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-139193, filed on 2 May 2002, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Edward T. Wei, 480 Grizzly Peak Blvd., Berkeley, CA, 94708
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 858
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A therapeutic composition is provided that comprises a 1-R1-phenyl, 4-R2-phenyl substituted 1,2,3,6-tetrahydropyrimidine-2-one sensory nerve receptor agonist in a therapeutically effective amount. The sensory nerve receptor agonist may be represented by the general formula 1-[R1-phenyl]-4-[R2-phenyl]-1,2,3,6-tetrahydropyrimidine-2-one wherein: R1 is -hydroxy, -chloro, -fluoro, -alkyl, -acetoxy, -trifluoromethyl; and R2 is -nitro, -chloro, -fluoro, -alkyl, -trifluoromethyl. Therapeutic compositions of the invention reduce pain, itch, and a sense of discomfort, when formulated for topical delivery to the human lips, mouth, and to the anorectal area.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 6 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2003:294885 USPATFULL
TITLE: 1,2,3,6-tetrahydropyrimidine-2-one compositions and therapeutic methods therewith for sexual disfunction
INVENTOR(S): Wei, Edward T., Berkeley, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003207903	A1	20031106
APPLICATION INFO.:	US 2002-191481	A1	20020708 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-139193, filed on 2 May 2002, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Edward T. Wei, 480 Grizzly Peak Blvd., Berkeley, CA, 94708
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 721
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A therapeutic composition is provided that comprises a 1-R1-phenyl, 4-R2-phenyl substituted 1,2,3,6-tetrahydropyrimidine-2-one sensory nerve receptor agonist in a therapeutically effective amount. The sensory nerve receptor agonist may be represented by the general formula 1-[R1-phenyl]-4-[R2-phenyl]-1,2,3,6-tetrahydropyrimidine-2-one wherein: R1 is -hydroxy, -chloro, - fluoro, -alkyl, -acetoxy, -trifluoromethyl ; and R2 is -nitro, -chloro, -fluoro, -alkyl,

-trifluoromethyl. Therapeutic compositions of the invention elicit soothing, cooling, and stimulatory effects when formulated for topical delivery to human sexual organs and to anorectal areas of the body and are useful to alleviate dysfunction in sexual response and intercourse for both men and women.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 7 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2003:294833 USPATFULL
TITLE: Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
INVENTOR(S): Wei, Edward T., Berkeley, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003207851	A1	20031106
APPLICATION INFO.:	US 2002-139193	A1	20020502 (10)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Edward T. Wei, 480 Grizzly Peak Blvd., Berkeley, CA, 94708
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 1224
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A therapeutic composition is provided that comprises a 1-R1-phenyl, 4-R2-phenyl substituted 1,2,3,6-tetrahydropyrimidine-2-one cold receptor agonist in a therapeutically effective amount and preferably further comprises one or more pharmaceutically active drugs such as an anti-inflammatory glucocorticosteroid, a sympathomimetic amine decongestant, an anti-histamine, a local anesthetic, menthol or a menthol analog, and mixtures thereof. The cold receptor agonist may be represented by the general formula 1-[1R-phenyl]-4-[R2-phenyl]-1,2,3,6-tetrahydropyrimidine-2-one wherein: R1 is -hydroxy, -chloro, -fluoro, -alkyl, -acetoxy, -trifluoromethyl; and R2 is -nitro, -chloro, -fluoro, -alkyl, -trifluoromethyl. Therapeutic compositions of the invention elicit long-lasting cooling or soothing, particularly when formulated for delivery to suppress the sensations of itch and pain, such as for delivery to inflamed skin, to the mucous membranes of the anogenital areas, and to the enteric mucosa.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 8 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2003:293861 USPATFULL
TITLE: 1,2,3,6-tetrahydropyrimidine-2-one compositions and therapeutic methods therewith for gastrointestinal dysfunction
INVENTOR(S): Wei, Edward T., Berkeley, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003206873	A1	20031106
APPLICATION INFO.:	US 2002-233126	A1	20020829 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-139193, filed on 2 May 2002, PENDING
DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Edward T. Wei, 480 Grizzly Peak Blvd., Berkeley, CA, 94708
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 724
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A therapeutic composition is provided that comprises a 1-R1-phenyl, 4-R2-phenyl substituted 1,2,3,6-tetrahydropyrimidine-2-one sensory nerve receptor agonist in a therapeutically effective amount. The sensory nerve receptor agonist may be represented by the general formula 1-[R1-phenyl]-4-[R2-phenyl]-1,2,3,6-tetrahydropyrimidine-2-one wherein: R1 may be -hydroxy, -chloro, -fluoro, -alkyl, -acetoxy, -trifluoromethyl ; and R2 is -nitro, -chloro, -fluoro, -alkyl, -trifluoromethyl. Therapeutic compositions of the invention reduce pain, a sense of abdominal distension, tenesmus, and abnormal bowel function when formulated for oral delivery to human gastrointestinal tract and are useful to alleviate gastrointestinal dysfunction.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 9 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2003:293854 USPATFULL
TITLE: 1,2,3,6-Tetrahydropyrimidine-2-one compositions, articles and therapeutic methods for upper airway breathing disorders
INVENTOR(S): Wei, Edward T., Berkeley, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003206866	A1	20031106
APPLICATION INFO.:	US 2002-267896	A1	20021008 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-139193, filed on 2 May 2002, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Edward T. Wei, 480 Grizzly Peak Blvd., Berkeley, CA, 94708
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 995
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A therapeutic composition is provided that comprises a 1-R1-phenyl, 4-R2-phenyl substituted 1,2,3,6-tetrahydropyrimidine-2-one cold receptor agonist in a therapeutically effective amount. The cold receptor agonist may be represented by the general formula 1-[R1-phenyl]-4-[R2-phenyl]-1,2,3,6 -tetrahydropyrimidine-2-one wherein: R1 is -hydroxy, -chloro, -fluoro, -alkyl, -acetoxy, -trifluoromethyl; and R2 is -nitro, -chloro, -fluoro, -alkyl, -trifluoromethyl. Therapeutic compositions of the invention when formulated for delivery to the mucous membranes of the nose and throat alleviate the sensations of airway obstruction and provide symptomatic relief of upper airway breathing disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

(FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 12:15:26 ON 30 MAR 2005)
L13 9 S L10
L14 6 DUP REM L13 (3 DUPLICATES REMOVED)

L14 ANSWER 1 OF 6 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
ACCESSION NUMBER: 2004251622 EMBASE
TITLE: TRPM8 activation by menthol, icilin, and cold is differentially modulated by intracellular pH.
AUTHOR: Andersson D.A.; Chase H.W.N.; Bevan S.
CORPORATE SOURCE: Dr. D.A. Andersson, Novartis Inst. for Medical Sciences, 5 Gower Place, London WC1E 6BS, United Kingdom. David.Andersson@pharma.novartis.com
SOURCE: Journal of Neuroscience, (9 Jun 2004) 24/23 (5364-5369).
Refs: 23
ISSN: 0270-6474 CODEN: JNRSDS
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 008 Neurology and Neurosurgery
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
AB TRPM8 is a nonselective cation channel activated by cold and the cooling compounds menthol and icilin (Peier et al., 2002). Here, we have used electrophysiology and the calcium-sensitive dye Fura-2 to study the effect of pH and interactions between temperature, pH, and the two chemical agonists menthol and icilin on TRPM8 expressed in Chinese hamster ovary cells. Menthol, icilin, and cold all evoked stimulus-dependent [Ca(2+)](i) responses in standard physiological solutions of pH 7.3. Increasing the extracellular [H(+)] from pH 7.3 to approximately pH 6 abolished responses to icilin and cold stimulation but did not affect responses to menthol. Icilin concentration-response curves were significantly shifted to the right when pH was lowered from 7.3 to 6.9, whereas those with menthol were unaltered in solutions of pH 6.1. When cells were exposed to solutions in the range of pH 8.1-6.5, the temperature threshold for activation was elevated at higher pH and depressed at lower pH. Superfusing cells with a low subactivating concentration of icilin or menthol elevated the threshold for cold activation at pH 7.4, but cooling failed to evoke [Ca(2+)](i) responses at pH 6 in the presence of either agonist. In voltage-clamp experiments in which the intracellular pH was buffered to different levels, acidification reduced the current amplitude of icilin responses and shifted the threshold for cold activation to lower values with half-maximal inhibition at pH 7.2 and pH 7.6. The results demonstrate that the activation of TRPM8 by icilin and cold, but not menthol, is modulated by intracellular pH in the physiological range. Furthermore, our data suggest that activation by icilin and cold involve a different mechanism to activation by menthol.

L14 ANSWER 2 OF 6 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
ACCESSION NUMBER: 2004393453 EMBASE
TITLE: The super-cooling agent icilin reveals a mechanism of coincidence detection by a temperature-sensitive TRP channel.
AUTHOR: Chuang H.-H.; Neuhausser W.M.; Julius D.
CORPORATE SOURCE: D. Julius, Dept. of Cell. and Molec. Pharmacol., University of California, San Francisco, 94143, San Francisco, CA, United States. julius@cmp.ucsf.edu
SOURCE: Neuron, (16 Sep 2004) 43/6 (859-869).

Refs: 50
ISSN: 0896-6273 CODEN: NERNET
PUBLISHER IDENT.: S 0896-6273(04)00538-0
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 002 Physiology
008 Neurology and Neurosurgery
029 Clinical Biochemistry
LANGUAGE: English
SUMMARY LANGUAGE: English

AB TRPM8, a member of the transient receptor potential family of ion channels, depolarizes somatosensory neurons in response to cold. TRPM8 is also activated by the cooling agents menthol and icilin. When exposed to menthol or cold, TRPM8 behaves like many ligand-gated channels, exhibiting rapid activation followed by moderate Ca(2+)-dependent adaptation. In contrast, icilin activates TRPM8 with extremely variable latency followed by extensive desensitization, provided that calcium is present. Here, we show that, to achieve full efficacy, icilin requires simultaneous elevation of cytosolic Ca(2+), either via permeation through TRPM8 channels or by release from intracellular stores. Thus, two stimuli must be paired to elicit full channel activation, illustrating the potential for coincidence detection by TRP channels. Determinants of icilin sensitivity map to a region of TRPM8 that corresponds to the capsaicin binding site on the noxious heat receptor TRPV1, suggesting a conserved molecular logic for gating of these thermosensitive channels by chemical agonists.

L14 ANSWER 3 OF 6 EMBASE on STN

ACCESSION NUMBER: 2004159204 EMBASE
TITLE: Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay.
AUTHOR: Behrendt H.-J.; Germann T.; Gillen C.; Hatt H.; Jostock R.
CORPORATE SOURCE: H.-J. Behrendt, Grunenthal GmbH, Molecular Pharmacology, Aachen 52099, Germany. Hans-Joerg.Behrendt@grunenthal.de
SOURCE: British Journal of Pharmacology, (2004) 141/4 (737-745).
Refs: 46
ISSN: 0007-1188 CODEN: BJPCBM
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 002 Physiology
029 Clinical Biochemistry
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English

AB 1 TRPM8 (CMR1) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, eucalyptol and icilin. It belongs to the transient receptor potential (TRP) family, and therefore is related to vanilloid receptor type-1 (VR1, TRPV1). We tested whether substances which are structurally related to menthol, or which produce a cooling sensation, could activate TRPM8, and compared the responses of TRPM8 and VR1 to these ligands. 2 The effects of 70 odorants and menthol-related substances on recombinant mouse TRPM8 (mTRPM8), expressed in HEK293 cells, were examined using a FLIPR® assay. In all, 10 substances (linalool, geraniol, hydroxycitronellal, WS-3,

WS-23, FrescolatMGA, FrescolatML, PMD38, CoolactP and Cooling Agent 10) were found to be agonists. 3 The EC(50) values of the agonists defined their relative potencies: icilin (0.2 ± 0.1 μM) > FrescolatML (3.3 ± 1.5 μM) > WS-3 (3.7 ± 1.7 μM) (-)menthol (4.1 ± 1.3 μM) frescolatMAG (4.8 ± 1.1 μM) > cooling agent 10 (6 ± 2.2 μM) (+)menthol (14.4 ± 1.3 μM) > PMD38 (31 ± 1.1 μM) > WS-23 (44 ± 7.3 μM) > Coolact P (66 ± 20 μM) > geraniol (5.9 ± 1.6 mM) > linalool (6.7 ± 2.0 mM) > eucalyptol (7.7 ± 2.0 mM) > hydroxycitronellal (19.6 ± 2.2 mM). 4 Known VR1 antagonists (BCTC, thio-BCTC and capsazepine) were also able to block the response of TRPM8 to menthol (IC (50): 0.8 ± 1.0, 3.5 ± 1.1 and 18 ± 1.1 μM, respectively). 5 The Ca(2+) response of hVR1-transfected HEK293 cells to the endogenous VR1 agonist N-arachidonoyl-dopamine was potentiated by low pH. In contrast, menthol- and icilin-activated TRPM8 currents were suppressed by low pH. 6 In conclusion, in the present study, we identified 10 new agonists and three antagonists of TRPM8. We found that, in contrast to VR1, TRPM8 is inhibited rather than potentiated by protons.

L14 ANSWER 4 OF 6 MEDLINE on STN DUPLICATE 1
ACCESSION NUMBER: 83163665 MEDLINE
DOCUMENT NUMBER: PubMed ID: 6131976
TITLE: AG-3-5: a chemical producing sensations of cold.
AUTHOR: Wei E T; Seid D A
SOURCE: Journal of pharmacy and pharmacology, (1983 Feb) 35 (2) 110-2.
Journal code: 0376363. ISSN: 0022-3573.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198305
ENTRY DATE: Entered STN: 19900318
Last Updated on STN: 19950206
Entered Medline: 19830527

L14 ANSWER 5 OF 6 MEDLINE on STN DUPLICATE 2
ACCESSION NUMBER: 81165000 MEDLINE
DOCUMENT NUMBER: PubMed ID: 6783443
TITLE: RX 336-M, a new chemical tool in the analysis of the quasi-morphine withdrawal syndrome.
AUTHOR: Cowan A
CONTRACT NUMBER: SO7 RR05417 (NCRR)
SOURCE: Federation proceedings, (1981 Apr) 40 (5) 1497-501.
Journal code: 0372771. ISSN: 0014-9446.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198106
ENTRY DATE: Entered STN: 19900316
Last Updated on STN: 19970203
Entered Medline: 19810623

AB RX 336-M (7,8-dihydro-5',6'-dimethylcyclohex-5'-eno-1',2',8',14 codeinone) and four other chemically-diverse agents--AG-3-5 (1-[2-hydroxyphenyl]-4-[3-nitrophenyl]-1,2,3,6-tetrahydropyrimidine-2-one), Sgd 8473 (alpha-[4-chlorobenzylideneamino)-oxy]-isobutyric acid), thyrotropin releasing hormone (TRH), and sodium valproate--each induce signs of withdrawal, most notably 'wet-dog' shaking, after

acute i.p. administration in drug-naive rats. They are therefore additions to a recently recognized and, as yet, ill-defined class of behaviorally active compounds. The pharmacological baselines that link these disparate agents together have been studied in the present work, using 'wet-dog' shaking as the behavioral measure and RX 336-M as the reference shake-inducing compound. Peripheral administration of clonidine, haloperidol, d-lysergic acid diethylamide, or morphine suppressed chemically induced shaking: naloxone had no marked effect. Reverse tolerance was associated with TRH-induced shaking whereas tolerance occurred with the other four compounds. Cross-tolerance interactions were asymmetrical. Thus, rats rendered tolerant to RX 336-M were cross-tolerant to AG-3-5, TRH, and sodium valproate but not to Sgd 8473; in contrast, RX 336-M-induced shaking was only significantly reduced in rats made tolerant to Sgd 8473. In view of the unidirectional nature of the cross-tolerance relationships studied, it is concluded that AG-3-5, Sgd 8473, sodium valproate, and TRH initiate 'wet-dog' shaking through neural substrates that differ from the one(s) associated with RX 336-M. Nevertheless, all five compounds may eventually trigger a common shake-inducing mechanism.

L14 ANSWER 6 OF 6 MEDLINE on STN DUPLICATE 3
ACCESSION NUMBER: 81164999 MEDLINE
DOCUMENT NUMBER: PubMed ID: 6260535
TITLE: Pharmacological aspects of shaking behavior produced by TRH, AG-3-5, and morphine withdrawal.
AUTHOR: Wei E T
SOURCE: Federation proceedings, (1981 Apr) 40 (5) 1491-6. Journal code: 0372771. ISSN: 0014-9446.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198106
ENTRY DATE: Entered STN: 19900316
Last Updated on STN: 19970203
Entered Medline: 19810623

AB In virtually all fur-coated and feathered animals, shaking movements of the body, similar to that made by a dog when wet, occur in response to irritation of the skin or in response to sensations of intense cold. Vigorous shaking movements occur in rats undergoing opiate withdrawal. I was led by this observation to investigations on the pharmacology of agents that stimulate or inhibit shaking. Thyrotropin-releasing hormone, injected centrally at submicrogram doses, produced in nondependent, barbiturate-anesthetized animals, shaking behavior identical in its general features to that of morphine withdrawal. AG-3-5 (1-[2-hydroxyphenyl]-4[3-nitrophenyl]-1,2,3,6-tetrahydropyrimidine-2-one), another chemical stimulant of shaking, produced specific sensations of cold in man by a peripheral site of action. In this context, it should be noted that sensations of cold, and the associated emotional discomfort, are conspicuous symptoms of opiate withdrawal in man. Shaking movements elicited by a variety of stimuli were inhibited by central administration of nanomolar doses of drugs that act as agonists on opiate, muscarinic, and alpha-adrenergic receptors. These observations may provide information on a) the identity of substances in brain that, when released, provoke opiate withdrawal signs and symptoms; b) the chemical nature of substances that stimulate peripheral cold receptors; and c) the pharmacologic classification of centrally acting agents that attenuate withdrawal and produce antinociception.

(FILE 'MARPAT' ENTERED AT 12:15:51 ON 30 MAR 2005)

L15 STR



VAR G1=H/23/OH/N/24/21
NODE ATTRIBUTES:
CONNECT IS X2 RC AT 8
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 22 23 24
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE

ATTRIBUTES SPECIFIED AT SEARCH-TIME:
ECLEVEL IS LIM ON ALL NODES
ALL RING(S) ARE ISOLATED

L17 15 SEA FILE=MARPAT SSS FUL L15 (MODIFIED ATTRIBUTES)

100.0% PROCESSED 1986 ITERATIONS 15 ANSWERS
SEARCH TIME: 00.00.03

L17 ANSWER 1 OF 15 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 141:88219 MARPAT
TITLE: Compound delivery systems comprising a cooling compound such as menthol or icilin
INVENTOR(S): Appelqvist, Ingrid Anne Marie; Malone, Mark Emmett; Nandi, Asish
PATENT ASSIGNEE(S): Unilever PLC, UK; Unilever NV; Hindustan Lever Limited
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056332	A1	20040708	WO 2003-EP14179	20031210

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004151674	A1	20040805	US 2003-740252	20031218

PRIORITY APPLN. INFO.: GB 2002-29811 20021220

AB A composition comprising (a) from 0.005% to 0.5% by weight of a cooling compound; (b) from 0.1% to 10% by weight of an emulsifiable substance;(c) from 0.15% to 15% by weight of a surfactant; and (d) optionally up to 5% by weight, preferably from 0.05% to 5% by weight of a cosurfactant. The cooling compound is preferably icilin or menthol. The composition is to be used in toothpastes, mouthwashes, beverages, water ice, spreads, dressings or ice cream. For example, a fruit flavored tea beverage contained (by weight) sugar 7.2%, tea powder 0.14%, acids & salts 0.215%, fruit juice & flavor 0.38%, Brij 96 0.15%, glycerol 0.05%, medium-chain triglycerides 0.1%, cooling active 0.005%, and water to 100%. It was found that using as cooling active, resp. menthol or 1-(2'-methoxyphenyl)-4-(3''-nitrophenyl)-1,2,3,6-tetrahydropyrimidin-2-one, ingestion in the form of the composition of the above example prolonged the cooling effect perceived, relative to the same amount of the cooling active alone.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 15 MARPAT COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 140:303686 MARPAT

TITLE: Tetrahydropyrimidine-2-one derivatives and their uses, particularly for producing a cooling sensation, and application to oral and personal hygiene products and foodstuffs.

INVENTOR(S): Foster, Alison; Van der Logt, Cornelis Paul Erik; Tareilus, Erwin Werner

PATENT ASSIGNEE(S): Unilever PLC, UK; Unilever NV; Hindustan Lever Limited

SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026840	A1	20040401	WO 2003-EP9566	20030826

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004067970 A1 20040408 US 2003-664367 20030917

PRIORITY APPLN. INFO.: GB 2002-21697 20020918

GI



I



II



III

AB Use of compds. I or their salts to produce a cooling sensation is disclosed [wherein: R1 and R2 = H, halo, OH, cyano, NO2, SH, CO, sulfone, carboxy, (un)substituted alkyl, alkenyl, alkoxy, alkylthio, aryl, aryloxy, arylthio, amino, siloxy, ester, or heterocyclic, with the proviso that R1 = 2-hydroxyphenyl, R2 = 3-nitrophenyl, i.e., icilin (II), is excluded]. II is a known cooling-sensation-producing compound with advantages over menthol, including greater potency and lower acute toxicity. Approx. 10 specific compds. are claimed. Claimed uses include toothpaste, mouthwash, beverages, ice cream, and confectionaries. For instance, compound III was prepared in 3 steps: (1) α-aminomethylation of 3-ClC6H4COMe with CH2(NMe2)2 (84%); (2) amine substitution of the dimethylamino group in the product by 2-aminophenol (40%); and (3) cyclocondensation of the obtained amino ketone 3-ClC6H4COCH2CH2NHC6H4OH-2.HCl with potassium cyanate to form the tetrahydropyrimidinone ring (41%). In a test for effects on cultured rat trigeminal neurons (measured by monitoring cellular Ca2+ levels), III had activity (35% vs. II) comparable to that of menthol (42% vs. II).

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE

RE FORMAT

L17 ANSWER 3 OF 15 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 139:354482 MARPAT
TITLE: Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
INVENTOR(S): Wei, Edward T.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 13 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003207851	A1	20031106	US 2002-139193	20020502
US 2003207903	A1	20031106	US 2002-191481	20020708
US 2003207904	A1	20031106	US 2002-232798	20020829
US 6743801	B2	20040601		
US 2003206873	A1	20031106	US 2002-233126	20020829
US 2003206866	A1	20031106	US 2002-267896	20021008
WO 2003092697	A1	20031113	WO 2003-GB1811	20030428
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1503763	A1	20050209	EP 2003-718956	20030428
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.:

US 2002-139193	20020502
US 2002-191481	20020708
US 2002-232798	20020829
US 2002-233126	20020829
US 2002-267896	20021008
WO 2003-GB1811	20030428

AB A therapeutic composition is provided that comprises a 1,2,3,6-tetrahydropyrimidine-2-one derivative cold receptor agonist in a therapeutically effective amount and preferably further comprises one or more pharmaceutically active drugs such as an anti-inflammatory glucocorticosteroid, a sympathomimetic amine decongestant, an antihistamine, a local anesthetic, menthol or a menthol analog, and mixts. thereof. Therapeutic compns. of the invention elicit long-lasting cooling or soothing, particularly when formulated for delivery to suppress the sensations of itch and pain, such as for delivery to inflamed skin, to the mucous membranes of the anogenital areas, and to the enteric mucosa. For example, a male subject with an abrasion on his finger of about 1 cm2 received 0.8 mg of icilin applied directly to the wound with a swab stick. The dull pain previously present at the wound site began to feel cold and the pain was lessened.

L17 ANSWER 4 OF 15 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 139:354472 MARPAT
TITLE: Inhalable compositions containing 1,2,3,6-tetrahydropyrimidine-2-one derivatives and other actives for upper airway breathing disorders
INVENTOR(S): Wei, Edward T.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 10 pp., Cont.-in-part of U.S. Ser. No. 139,193.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003206866	A1	20031106	US 2002-267896	20021008
US 2003207851	A1	20031106	US 2002-139193	20020502
WO 2003092697	A1	20031113	WO 2003-GB1811	20030428
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1503763	A1	20050209	EP 2003-718956	20030428
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.:
US 2002-139193 20020502
US 2002-191481 20020708
US 2002-232798 20020829
US 2002-233126 20020829
US 2002-267896 20021008
WO 2003-GB1811 20030428

AB A therapeutic composition is provided that comprises a 1,2,3,6-tetrahydropyrimidine-2-one derivative cold receptor agonist in a therapeutically effective amount Therapeutic compns. of the invention when formulated for delivery to the mucous membranes of the nose and throat alleviate the sensations of airway obstruction and provide symptomatic relief of upper airway breathing disorders. A 10 % icilin dissolved in propylene glycol was mixed 1:5 with Ayr Saline Nasal Mist to yield a 2 % concentration The icilin-saline spray mist was applied intranasally to a subject with nasal congestion from seasonal allergic rhinitis. Sensations of coolness were experienced and the sense of nasal obstruction was relieved.

L17 ANSWER 5 OF 15 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 139:345959 MARPAT
TITLE: 1,2,3,6-Tetrahydropyrimidine-2-one compositions and therapeutic methods for sexual disfunction
INVENTOR(S): Wei, Edward T.
PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 8 pp., Cont.-n-part of U.S. Ser. No. 139,193.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003207903	A1	20031106	US 2002-191481	20020708
US 2003207851	A1	20031106	US 2002-139193	20020502
WO 2003092697	A1	20031113	WO 2003-GB1811	20030428
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1503763	A1	20050209	EP 2003-718956	20030428
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.:

US 2002-139193	20020502
US 2002-191481	20020708
US 2002-232798	20020829
US 2002-233126	20020829
US 2002-267896	20021008
WO 2003-GB1811	20030428

AB A therapeutic composition is provided that comprises a substituted 1,2,3,6-tetrahydropyrimidine-2-one sensory nerve receptor agonist in a therapeutically effective amount The sensory nerve receptor agonist is 1-[R1-phenyl]-4-[R2-phenyl]-1,2,3,6-tetrahydropyrimidine-2-one (R1 = OH, Cl, F, alkyl, acetoxy, CF3; R2 = nitro, Cl, F, -alkyl, CF3). Therapeutic compns. of the invention elicit soothing, cooling, and stimulatory effects when formulated for topical delivery to human sexual organs and to anorectal areas of the body and are useful to alleviate dysfunction in sexual response and intercourse for both men and women.

L17 ANSWER 6 OF 15 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 139:345942 MARPAT
TITLE: 1,2,3,6-Tetrahydropyrimidine-2-one compositions and therapeutic methods for pain and inflammation
INVENTOR(S): Wei, Edward T.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 9 pp., Cont.-in-part of U.S. Ser. No. 139,193.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 2003207904	A1	20031106	US 2002-232798	20020829
US 6743801	B2	20040601		
US 2003207851	A1	20031106	US 2002-139193	20020502
WO 2003092697	A1	20031113	WO 2003-GB1811	20030428

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1503763	A1	20050209	EP 2003-718956	20030428

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.:

US 2002-139193	20020502
US 2002-191481	20020708
US 2002-232798	20020829
US 2002-233126	20020829
US 2002-267896	20021008
WO 2003-GB1811	20030428

AB A therapeutic composition is provided that comprises a substituted 1,2,3,6-tetrahydropyrimidine-2-one sensory nerve receptor agonist in a therapeutically effective amount The sensory nerve receptor agonist is 1-[R1-phenyl]-4-[R2-phenyl]-1,2,3,6-tetrahydropyrimidine-2-one (R1 = OH, Cl, F, alkyl, acetoxy, CF3; R2 = nitro, Cl, F, alkyl, CF3). Therapeutic compns. of the invention reduce pain, itch, and a sense of discomfort, when formulated for topical delivery to the human lips, mouth, and to the anorectal area.

L17 ANSWER 7 OF 15 MARPAT COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 139:345928 MARPAT

TITLE: 1,2,3,6-Tetrahydropyrimidine-2-one compositions and therapeutic methods for gastrointestinal dysfunction

INVENTOR(S): Wei, Edward T.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 8 pp., Cont.-in-part of U.S. Ser. No. 139,193.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003206873	A1	20031106	US 2002-233126	20020829
US 2003207851	A1	20031106	US 2002-139193	20020502
WO 2003092697	A1	20031113	WO 2003-GB1811	20030428

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,

TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1503763	A1	20050209	EP 2003-718956	20030428

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.:	US 2002-139193	20020502
	US 2002-191481	20020708
	US 2002-232798	20020829
	US 2002-233126	20020829
	US 2002-267896	20021008
	WO 2003-GB1811	20030428

AB A therapeutic composition is provided that comprises a substituted 1,2,3,6-tetrahydropyrimidine-2-one sensory nerve receptor agonist in a therapeutically effective amount The sensory nerve receptor agonist is 1-[R1-phenyl]-4-[R2-phenyl]-1,2,3,6-tetrahydropyrimidine-2-one (R1 = OH, Cl, F, alkyl, acetoxy, CF3; R2 = nitro, Cl, F, alkyl, CF3). Therapeutic compns. of the invention reduce pain, a sense of abdominal distension, tenesmus, and abnormal bowel function when formulated for oral delivery to human gastrointestinal tract and are useful to alleviate gastrointestinal dysfunction.

L17 ANSWER 8 OF 15 MARPAT COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:	135:331438 MARPAT
TITLE:	Preparation of heterocyclic compounds for the treatment of diabetes and related diseases
INVENTOR(S):	Lohray, Vidya Bhushan; Lohray, Braj Bhushan; Paraselli, Rao Bheema; Gurram, Ranga Madhavan; Ramanujam, Rajagopalan; Chakrabarti, Ranjan; Pakala, Sarma K. S.
PATENT ASSIGNEE(S):	Reddy's Research Foundation, India; Reddy-Cheminor Inc.
SOURCE:	U.S., 35 pp., Cont.-in-part of U.S. 5,985,884. CODEN: USXXAM
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6310069	B1	20011030	US 2000-535387	20000324
US 5885997	A	19990323	US 1996-777627	19961231
US 5985884	A	19991116	US 1997-884816	19970630

PRIORITY APPLN. INFO.:	US 1996-777627	19961231
	US 1997-884816	19970630
	IN 1996-MA1150	19960701

GI



I



II

AB The title compds. [I; one of X, Y, Z = C(O), C(S) and one of the remaining of X, Y, Z = C or C:C; R1-R3 = H, halo, OH, etc.; n = 1-4; Ar = (un)substituted divalent aryl, heteroaryl; R4 = H, halo, alkyl or forms a bond together with the adjacent group A; A = N, CR5 (wherein R5 = H, halo, alkyl or R5 forms a bond together with R4); B = O, S when A = CR5 and B = O when A = N], novel antidiabetic compds., were prepared and formulated. Thus, reacting 4-[2-(2-ethyl-4-methyl-6-oxo-1,6-dihydro-1-pyrimidinyl)ethoxy]benzaldehyde (preparation given) with thiazolidine-2,4-dione afforded II which showed 67% maximum reduction in blood glucose level at 100 mg/kg/day (6 days treatment) in mice.

REFERENCE COUNT: 95 THERE ARE 95 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 9 OF 15 MARPAT COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 132:180493 MARPAT

TITLE: Preparation of dibenzo[a,g]quinolizinium derivatives as sterol 14-reductase inhibitors

INVENTOR(S): Kim, Jung Ho; Jhong, Tae Neung; Paik, Young Ki; Park, Joon Seo; Kim, Eui Deok; Lee, You Suk; Kim, Seung Un

PATENT ASSIGNEE(S): Hanwha Corporation, Peop. Rep. China

SOURCE: U.S., 27 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6030979	A	20000229	US 1999-235489	19990122
KR 2000042507	A	20000715	KR 1998-58722	19981221
CA 2355469	AA	20000629	CA 1999-2355469	19990119
WO 2000037468	A1	20000629	WO 1999-KR30	19990119

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HR, HU, ID, IL, IS, KP, KR, KZ,

LC, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TR, UA, UZ, VN, YU
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

AU 9920776	A1	20000712	AU 1999-20776	19990119
AU 777377	B2	20041014		
BR 9916431	A	20010904	BR 1999-16431	19990119
EP 1140930	A1	20011010	EP 1999-901239	19990119
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
RU 2223962	C2	20040220	RU 2001-117070	19990119
JP 2000191662	A2	20000711	JP 1999-68214	19990315
PRIORITY APPLN. INFO.:			KR 1998-58722	19981221
			WO 1999-KR30	19990119

GI



I

AB The title compds. (I) [wherein R1 and R2 = independently OH or alkoxy, or together form a methylenedioxy group; R3 = OH or alkoxy; R4 = alkyl or alkenyl; X = inorg. acid ion, organic acid ion, or halide; Z = alkyl, alkenyl, N-benzotriazolyl, quinolinyl, (un)substituted furyl, or (un)substituted Ph, pyridinyl, or pyrimidinyl] were prepared for use in the treatment of hypercholesterolemia or hyperlipidemia. Examples include 71 syntheses, in vitro and in vivo bioassays demonstrating inhibition of sterol 14-reductase activity and cholesterol biosynthesis, 6 pharmaceutical formulations, and a toxicity study on 4 representative compds. For instance, I [R1-R3 = MeO; R4 = Et; Z = pentafluorophenyl; X = Cl] was prepared in a 3-step sequence from I [R1 and R2 = -OCH2O-; R3 = MeO; R4 = Et; Z = H; X = Cl]. The pentafluorobenzyl compound (1) inhibited sterol 14-reductase activity in rat microsome protein with an IC50 of ≤ 1 μM; (2) markedly decreased total cholesterol, LDL-cholesterol, and triglyceride levels in hamsters compared with lovastatin, a com. available cholesterol-lowering agent; and (3) proved nontoxic in rats with an LD50 of > 2000 mg/kg. Compds. of the invention also have the ability to lower blood glucose levels with concurrent reduction of cholesterol levels, rendering them effective against diabetic hypercholesterolemia and hyperlipidemia (no data).

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 10 OF 15 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 132:166129 MARPAT
TITLE: Preparation of dibenzo[a,g]quinolizinium derivatives as sterol 14-reductase inhibitors
INVENTOR(S): Kim, Jung Ho; Jhong, Tae Neung; Paik, Young Ki;

Park, Joon Seo; Kim, Eui Deok; Lee, You Suk; Kim, Seung Un
PATENT ASSIGNEE(S): Hanwha Corporation, S. Korea
SOURCE: U.S., 29 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6028197	A	20000222	US 1999-235482	19990122
KR 2000042507	A	20000715	KR 1998-58722	19981221
CA 2355469	AA	20000629	CA 1999-2355469	19990119
WO 2000037468	A1	20000629	WO 1999-KR30	19990119
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HR, HU, ID, IL, IS, KP, KR, KZ, LC, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TR, UA, UZ, VN, YU				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9920776	A1	20000712	AU 1999-20776	19990119
AU 777377	B2	20041014		
BR 9916431	A	20010904	BR 1999-16431	19990119
EP 1140930	A1	20011010	EP 1999-901239	19990119
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
RU 2223962	C2	20040220	RU 2001-117070	19990119
JP 2000191662	A2	20000711	JP 1999-68214	19990315
PRIORITY APPLN. INFO.:			KR 1998-58722	19981221
			WO 1999-KR30	19990119

GI



I

AB The title compds. [I; R1, R2 = OH, alkoxy; R1 and R2 together = methylenedioxy; R3 = OH, alkoxy; R4 = H, alkyl, alkenyl; X = inorg. acid ion, organic acid ion, halide; Z = alkyl, alkenyl, N-benzotriazolyl, etc.] which specifically inhibit the sterol 14-reductase which is involved in the distal pathway of cholesterol biosynthesis, and therefore are useful for treating hypercholesterolemia or hyperlipidemia, were prepared and formulated. E.g., a 3-step synthesis of I [R1-R3 = MeO; R4 = Et; Z = CH2(CH2)10Me; X = Cl], was presented. Biol. data for compds. I were given.

REFERENCE COUNT; 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 11 OF 15 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 131:351343 MARPAT
TITLE: Preparation of heterocyclic compounds for the treatment of diabetes and related diseases
INVENTOR(S): Lohray, Vidya Bhushan; Lohray, Braj Bhushan; Paraselli, Rao Bheema; Gurram, Ranga Madhavan; Ramanujam, Rajagopalan; Chakrabarti, Ranjan; Pakala, Sarma K. S.
PATENT ASSIGNEE(S): Reddy's Research Foundation, India; Reddy-Cheminor Inc.
SOURCE: U.S., 35 pp., Cont.-in-part of U.S. 5,885,997. CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5985884	A	19991116	US 1997-884816	19970630
US 5885997	A	19990323	US 1996-777627	19961231
US 6114526	A	20000905	US 1999-353286	19990714
US 6310069	B1	20011030	US 2000-535387	20000324
US 6573268	B1	20030603	US 2000-535388	20000324
US 2001031759	A1	20011018	US 2001-827009	20010405
US 6372750	B2	20020416		
US 2002123502	A1	20020905	US 2001-32846	20011226
US 6780992	B2	20040824		
US 2005032864	A1	20050210	US 2004-917221	20040812

PRIORITY APPLN. INFO.:
IN 1996-MA1150 19960701
US 1996-777627 19961231
US 1997-884816 19970630
US 1999-353286 19990714
US 2000-535388 20000324
US 2001-827009 20010405
US 2001-32846 20011226

GI



I



II

AB The title compds. [I; one of X, Y, Z = C(O), C(S) and one of the remaining of X, Y, Z = C and the other C:C; R1-R3 = H, halo, OH, etc.; n = 1-4; Ar = (un)substituted divalent aryl, heteroaryl; R4 = H, halo, alkyl or forms a bond together with the adjacent group A; A = N, CR5 (wherein R5 = H, halo, alkyl or R5 forms a bond together with R4); B = O, S when A = CR5 and B = O when A = N], novel antidiabetic compds., were prepared and formulated. Thus, reacting 4-[2-(2-ethyl-4-methyl-6-oxo-1,6-dihydro-1-pyrimidinyl)ethoxy]benzaldehyde (preparation given) with thiazolidine-2,4-dione afforded II which showed 67% maximum reduction in blood glucose level at 100 mg/kg/day (6 days treatment) in mice.

REFERENCE COUNT: 84 THERE ARE 84 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 12 OF 15 MARPAT COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 130:223293 MARPAT

TITLE: Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases

INVENTOR(S): Lohray, Vidya Bhushan; Lohray, Braj Bhushan; Paraselli, Rao Bheema

PATENT ASSIGNEE(S): Reddy's Research Foundation, India; Reddy-Cheminor, Inc.

SOURCE: U.S., 26 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5885997	A	19990323	US 1996-777627	19961231
CA 2258949	AA	19971106	CA 1997-2258949	19970630

WO 9741097		A2	19971106	WO 1997-US11522	19970630
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9737198		A1	19971119	AU 1997-37198	19970630
AU 744518		B2	20020228		
US 5985884		A	19991116	US 1997-884816	19970630
EP 958296		A1	19991124	EP 1997-934041	19970630
EP 958296		B1	20030730		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
BR 9711098		A	20000308	BR 1997-11098	19970630
CN 1275982		A	20001206	CN 1997-195778	19970630
JP 2002515874		T2	20020528	JP 1997-539307	19970630
IL 127296		A1	20030112	IL 1997-127296	19970630
RU 2200161		C2	20030310	RU 1998-123195	19970630
AT 246190		E	20030815	AT 1997-934041	19970630
PT 958296		T	20031128	PT 1997-934041	19970630
ES 2199366		T3	20040216	ES 1997-934041	19970630
ZA 9705866		A	19980223	ZA 1997-5866	19970701
MX 9810782		A	20001130	MX 1998-10782	19981215
NO 9806055		A	19981222	NO 1998-6055	19981222
US 6114526		A	20000905	US 1999-353286	19990714
US 6310069		B1	20011030	US 2000-535387	20000324
US 6573268		B1	20030603	US 2000-535388	20000324
US 2001031759		A1	20011018	US 2001-827009	20010405
US 6372750		B2	20020416		
US 2002123502		A1	20020905	US 2001-32846	20011226
US 6780992		B2	20040824		
US 2005032864		A1	20050210	US 2004-917221	20040812
PRIORITY APPLN. INFO.:				IN 1996-MA1150	19960701
				US 1996-777627	19961231
				US 1997-884816	19970630
				WO 1997-US11522	19970630
				US 1999-353286	19990714
				US 2000-535388	20000324
				US 2001-827009	20010405
				US 2001-32846	20011226

GI



I



II

AB The present invention relates to novel antidiabetic compds., their tautomeric forms, their derivs., their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compns. containing them. This invention particularly relates to novel azolidinedione derivs., and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compns. containing them. Approx. 30 title compds. such as I (R = Pr, Me, Et, Bu, benzyl) and their quinazoline analogs were prepared in 66-99% yields, e.g., by condensation of aldehydes II with thiazolidine-2,4-dione. Antidiabetic data was given for several of the prepared compds. At 30 mg/kg/day, after 6 days, 5-[4-[2-[2-ethyl-4-methyl-6-oxo-1,5-dihydro-1-pyrimidinyl]ethoxy]phenylmethyl] thiazolidine-2,4-dione reduced the blood glucose level 73%, lowered triglycerides 70% and also lowered cholesterol in the rat.

REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 13 OF 15 MARPAT COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 128:13282 MARPAT

TITLE: Preparation of thiazolidinediones and analogs as antidiabetics

INVENTOR(S): Lohray, Vidya Bhushan; Lohray, Braj Bhushan; Paraselli, Rao Bheema; Gurram, Ranga Madhavan; Ramanujam, Rajagopalan; Chakrabarti, Ranjan; Pakala, Sarma K. S.

PATENT ASSIGNEE(S): Dr. Reddy's Research Foundation, India; Reddy-Cheminor, Inc.

SOURCE: PCT Int. Appl., 112 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9741097	A2	19971106	WO 1997-US11522	19970630

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW

RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

US 5885997	A	19990323	US 1996-777627	19961231
AU 9737198	A1	19971119	AU 1997-37198	19970630
AU 744518	B2	20020228		
EP 958296	A1	19991124	EP 1997-934041	19970630
EP 958296	B1	20030730		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
BR 9711098	A	20000308	BR 1997-11098	19970630
JP 2002515874	T2	20020528	JP 1997-539307	19970630
IL 127296	A1	20030112	IL 1997-127296	19970630
RU 2200161	C2	20030310	RU 1998-123195	19970630
AT 246190	E	20030815	AT 1997-934041	19970630
MX 9810782	A	20001130	MX 1998-10782	19981215
NO 9806055	A	19981222	NO 1998-6055	19981222
PRIORITY APPLN. INFO.:			US 1996-777627	19961231
			IN 1996-MA1150	19960701
			WO 1997-US11522	19970630

GI



AB Title compds. [I; A = N, CR5; B = O or S; R = CHR4ZO(CH2)nR1; R1 = (un)substituted pyrimidinyl, -quinazolinyl, etc.; R4,R5 = H, halo, alkyl; R4R5 = bond; Z = divalent aromatic or heterocyclic group; n = 1-4] were prepared Thus, 4-methyl-2-propyl-1,6-dihydro-6-pyrimidinone was N-alkylated by 4-(BrCH2CH2O)C6H4CHO and the product condensed with thiazolidine-2,4-dione to give, after hydrogenation, title compound II. Data for biol. activity of I were given.

L17 ANSWER 14 OF 15 MARPAT COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 124:343323 MARPAT

TITLE: Preparation of tetrahydropyrimidinone derivatives as pesticides

INVENTOR(S): Mita, Takeshi; Numata, Akira; Ishii, Shigeru; Kudo, Masaki; Inoe, Yoichi; Myake, Toshiro

PATENT ASSIGNEE(S): Nissan Chemical Ind Ltd, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 36 pp. CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08027120	A2	19960130	JP 1994-157053	19940708

PRIORITY APPLN. INFO.: JP 1994-157053 19940708

GI



I



II

AB Tetrahydropyrimidinones [I; R1, R2 = H, C1-6 alkyl, C3-6 cycloalkyl; X1, X2 = halo, C1-4 alkyl, C1-4 alkoxy; Y = halo, C1-6 alkyl, C2-6 alkenyl; Z = O, S, NH; l = 0-4; m = 1-5], effective insecticides and miticides with no harmful effects on mammals and fish, are prepared A mixture of amine salt II and KOCN in HOAc was heated with stirring at 60° to give 87.1% I [R1 = R2 = H, X1 = F, (X2)l = 6-F, (Y)m = 4-Cl, Z = O], which killed 100% brown rice planthoppers at 1000 ppm.

L17 ANSWER 15 OF 15 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 122:289052 MARPAT
TITLE: Method for producing polypeptide
INVENTOR(S): Nitta, Itaru; Ueda, Takuya; Watanabe, Kimitsuna
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 14 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 646648	A1	19950405	EP 1994-115590	19941004
EP 646648	B1	20020130		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 07289282	A2	19951107	JP 1994-102861	19940517
JP 3603330	B2	20041222		
JP 07291991	A2	19951107	JP 1994-102862	19940517
JP 3555170	B2	20040818		

CA 2133355	AA	19950405	CA 1994-2133355	19940930
RU 2145976	C1	20000227	RU 1994-35681	19941003
US 5643744	A	19970701	US 1994-317356	19941004
AT 212673	E	20020215	AT 1994-115590	19941004
PRIORITY APPLN. INFO.:			JP 1993-248168	19931004
			JP 1994-34834	19940304
			JP 1994-34835	19940304
			JP 1994-102861	19940517
			JP 1994-102862	19940517

AB The present invention provides a method for producing a polypeptide, which comprises condensing precursors comprising an amino acid and an adaptor in the presence of ribosomes, rRNAs, a larger ribosomal subunit or ribosomal proteins, and an aromatic tertiary amine.

FILE 'MARPATPREV' ENTERED AT 12:18:43 ON 30 MAR 2005

L15 STR



VAR G1=H/23/OH/N/24/21
NODE ATTRIBUTES:
CONNECT IS X2 RC AT 8
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 22 23 24
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE

ATTRIBUTES SPECIFIED AT SEARCH-TIME:
ECLEVEL IS LIM ON ALL NODES
ALL RING(S) ARE ISOLATED

L18 0 SEA FILE=MARPATPREV SSS FUL L15 (MODIFIED ATTRIBUTES)

100.0% PROCESSED 1 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

(FILE 'CAPLUS, MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH,

```
     JICST-EPLUS, JAPIO' ENTERED AT 12:19:13 ON 30 MAR 2005)
L19         3725 S "FOSTER A"?/AU
L20           83 S ("VANDERLOGT C"? OR "VAN DER LOGT C"?)/AU
L21          114 S "TAREILUS E"?/AU
L22            2 S L19 AND L20 AND L21
L23            2 S L19 AND (L20 OR L21)
L24            2 S L20 AND L21
L25            2 S L22 OR L23 OR L24
L26            1 DUP REM L25 (1 DUPLICATE REMOVED)

L26  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2005 ACS on STN  DUPLICATE 1
ACCESSION NUMBER:         2004:267308  CAPLUS
DOCUMENT NUMBER:          140:303686
TITLE:                    Tetrahydropyrimidine-2-one derivatives and their
                          uses, particularly for producing a cooling
                          sensation, and application to oral and personal
                          hygiene products and foodstuffs.
INVENTOR(S):              Foster, Alison; Van der Logt,
                          Cornelis Paul Erik; Tareilus, Erwin
                          Werner
PATENT ASSIGNEE(S):       Unilever PLC, UK; Unilever NV; Hindustan Lever
                          Limited
SOURCE:                   PCT Int. Appl., 35 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     WO 2004026840         A1    20040401    WO 2003-EP9566           20030826
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
             NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
             SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA,
             ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
             NE, SN, TD, TG
     US 2004067970         A1    20040408    US 2003-664367           20030917
PRIORITY APPLN. INFO.:                     GB 2002-21697        A    20020918

OTHER SOURCE(S):          MARPAT 140:303686
GI
```



I



II



III

AB Use of compds. I or their salts to produce a cooling sensation is disclosed [wherein: R1 and R2 = H, halo, OH, cyano, NO2, SH, CO, sulfone, carboxy, (un)substituted alkyl, alkenyl, alkoxy, alkylthio, aryl, aryloxy, arylthio, amino, siloxy, ester, or heterocyclic, with the proviso that R1 = 2-hydroxyphenyl, R2 = 3-nitrophenyl, i.e., icilin (II), is excluded]. II is a known cooling-sensation-producing compound with advantages over menthol, including greater potency and lower acute toxicity. Approx. 10 specific compds. are claimed. Claimed uses include toothpaste, mouthwash, beverages, ice cream, and confectionaries. For instance, compound III was prepared in 3 steps: (1) α-aminomethylation of 3-ClC6H4COMe with CH2(NMe2)2 (84%); (2) amine substitution of the dimethylamino group in the product by 2-aminophenol (40%); and (3) cyclocondensation of the obtained amino ketone 3-ClC6H4COCH2CH2NHC6H4OH-2.HCl with potassium cyanate to form the tetrahydropyrimidinone ring (41%). In a test for effects on cultured rat trigeminal neurons (measured by monitoring cellular Ca2+ levels), III had activity (35% vs. II) comparable to that of menthol (42% vs. II).

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

FILE 'HOME' ENTERED AT 12:21:33 ON 30 MAR 2005